{"entity":"vertex-pharmaceuticals","id":"ent_vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","wikidata":"Q2744099","page":"https://asof.is/record/vertex-pharmaceuticals","summary":"Vertex Pharmaceuticals is an American pharmaceutical company, headquartered in Boston. It reported revenue of $12.00B for the period ended December 31, 2025.","title":"Vertex Pharmaceuticals: revenue $12.00B","key_facts":[{"label":"Headquarters","value":"Boston","claim":"clm_A5822A229828"},{"label":"Revenue","value":"$12.00B","recorded":"12,001,300,000 United States dollar","note":"to 2025-12-31","claim":"clm_B151EC07FDAE"},{"label":"Ticker","value":"VRTX · Nasdaq","claim":"clm_725C8AE3FDC6"}],"faq":[{"question":"Where is Vertex Pharmaceuticals headquartered?","answer":"Boston."},{"question":"What is Vertex Pharmaceuticals's revenue?","answer":"$12.00B for the period ended December 31, 2025."}],"as_of":null,"known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/vertex-pharmaceuticals/headquarters","md":"https://asof.is/record/vertex-pharmaceuticals/headquarters.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/vertex-pharmaceuticals/revenue","md":"https://asof.is/record/vertex-pharmaceuticals/revenue.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/revenue"},{"predicate":"net_income","page":"https://asof.is/record/vertex-pharmaceuticals/net_income","md":"https://asof.is/record/vertex-pharmaceuticals/net_income.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/vertex-pharmaceuticals/operating_income","md":"https://asof.is/record/vertex-pharmaceuticals/operating_income.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/vertex-pharmaceuticals/quarterly_revenue","md":"https://asof.is/record/vertex-pharmaceuticals/quarterly_revenue.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/quarterly_revenue"}],"products":[],"coverage":{"entity":"vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","kind":"organization","sources":[{"source":"wikidata","item":"Q2744099","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":875320,"ticker":"VRTX","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":553,"open":22,"retracted":0,"first":"2007-12-31","predicates":{"quarterly_operating_income":{"claims":54,"open":1,"kind":"fact"},"total_assets":{"claims":68,"open":1,"kind":"fact"},"total_equity":{"claims":70,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":54,"open":1,"kind":"fact"},"shares_outstanding":{"claims":67,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":40,"open":1,"kind":"fact"},"operating_income":{"claims":18,"open":1,"kind":"fact"},"revenue":{"claims":18,"open":1,"kind":"fact"},"research_and_development":{"claims":14,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":73,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":50,"open":1,"kind":"fact"},"net_income":{"claims":17,"open":1,"kind":"fact"},"agreement":{"claims":2,"open":2,"kind":"event"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":553,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_41CC1CCC4C8A","predicate":"shares_outstanding","value":"253,537,674 shares","valid_from":"2026-10-31","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,537,674 shares\", as of 2026-10-31. Claim clm_41CC1CCC4C8A, https://asof.is/claim/clm_41CC1CCC4C8A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_41CC1CCC4C8A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_088E22D9B313","predicate":"total_equity","value":"20,907,400,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 20,907,400,000 United States dollar\", as of 2026-09-30. Claim clm_088E22D9B313, https://asof.is/claim/clm_088E22D9B313, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_088E22D9B313","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_30E62BBC7C14","predicate":"quarterly_revenue","value":"3,440,800,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,440,800,000 United States dollar\", as of 2026-09-30. Claim clm_30E62BBC7C14, https://asof.is/claim/clm_30E62BBC7C14, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_30E62BBC7C14","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_40B40C0D43E5","predicate":"cash_and_equivalents","value":"4,979,300,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,979,300,000 United States dollar\", as of 2026-09-30. Claim clm_40B40C0D43E5, https://asof.is/claim/clm_40B40C0D43E5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_40B40C0D43E5","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_466B90DBA1DE","predicate":"quarterly_net_income","value":"653,600,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 653,600,000 United States dollar\", as of 2026-09-30. Claim clm_466B90DBA1DE, https://asof.is/claim/clm_466B90DBA1DE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_466B90DBA1DE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_60BA65E99F72","predicate":"quarterly_operating_income","value":"712,900,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 712,900,000 United States dollar\", as of 2026-09-30. Claim clm_60BA65E99F72, https://asof.is/claim/clm_60BA65E99F72, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_60BA65E99F72","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_E8F64842EB2A","predicate":"total_assets","value":"32,736,300,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 32,736,300,000 United States dollar\", as of 2026-09-30. Claim clm_E8F64842EB2A, https://asof.is/claim/clm_E8F64842EB2A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_E8F64842EB2A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_10753153913F","predicate":"shares_outstanding","value":"253,460,924 shares","valid_from":"2026-07-31","valid_to":"2026-10-31","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,460,924 shares\", as of 2026-07-31 (until 2026-10-31). Claim clm_10753153913F, https://asof.is/claim/clm_10753153913F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_10753153913F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_41CC1CCC4C8A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_14EDB54D4A3B","predicate":"agreement","value":"Crinetics Pharmaceuticals, Inc.","valid_from":"2026-07-06","valid_to":null,"published":"2026-07-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals agreement: Crinetics Pharmaceuticals, Inc.\", as of 2026-07-06. Claim clm_14EDB54D4A3B, https://asof.is/claim/clm_14EDB54D4A3B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm.","url":"https://asof.is/claim/clm_14EDB54D4A3B","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2026-07-07T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc.","url":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm"}},{"id":"clm_0B039E70EB86","predicate":"total_assets","value":"27,423,300,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 27,423,300,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_0B039E70EB86, https://asof.is/claim/clm_0B039E70EB86, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_0B039E70EB86","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E8F64842EB2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_0DE5C5FBB098","predicate":"cash_and_equivalents","value":"6,143,500,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 6,143,500,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_0DE5C5FBB098, https://asof.is/claim/clm_0DE5C5FBB098, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_0DE5C5FBB098","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_40B40C0D43E5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_3B40C30B5BFE","predicate":"quarterly_operating_income","value":"1,246,900,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,246,900,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_3B40C30B5BFE, https://asof.is/claim/clm_3B40C30B5BFE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_3B40C30B5BFE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60BA65E99F72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_5C5F8DB6F575","predicate":"quarterly_net_income","value":"1,099,800,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,099,800,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_5C5F8DB6F575, https://asof.is/claim/clm_5C5F8DB6F575, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_5C5F8DB6F575","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_466B90DBA1DE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_600A80B3AFE0","predicate":"quarterly_revenue","value":"3,333,900,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,333,900,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_600A80B3AFE0, https://asof.is/claim/clm_600A80B3AFE0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_600A80B3AFE0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30E62BBC7C14","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_DDD2C596A0EC","predicate":"total_equity","value":"20,247,900,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 20,247,900,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_DDD2C596A0EC, https://asof.is/claim/clm_DDD2C596A0EC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm.","url":"https://asof.is/claim/clm_DDD2C596A0EC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_088E22D9B313","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-04"}},{"id":"clm_EA3BCAE7F8D0","predicate":"shares_outstanding","value":"253,805,417 shares","valid_from":"2026-04-30","valid_to":"2026-07-31","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,805,417 shares\", as of 2026-04-30 (until 2026-07-31). Claim clm_EA3BCAE7F8D0, https://asof.is/claim/clm_EA3BCAE7F8D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_EA3BCAE7F8D0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_10753153913F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_0F975664C00F","predicate":"total_equity","value":"19,361,900,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 19,361,900,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_0F975664C00F, https://asof.is/claim/clm_0F975664C00F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_0F975664C00F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DDD2C596A0EC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_263F86EB65D1","predicate":"total_assets","value":"26,484,400,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 26,484,400,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_263F86EB65D1, https://asof.is/claim/clm_263F86EB65D1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_263F86EB65D1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0B039E70EB86","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_379D75861ABB","predicate":"cash_and_equivalents","value":"5,492,900,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 5,492,900,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_379D75861ABB, https://asof.is/claim/clm_379D75861ABB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_379D75861ABB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0DE5C5FBB098","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_58ABF4712193","predicate":"quarterly_net_income","value":"1,031,400,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,031,400,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_58ABF4712193, https://asof.is/claim/clm_58ABF4712193, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_58ABF4712193","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5C5F8DB6F575","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_78B1FE0A2ECC","predicate":"quarterly_revenue","value":"2,986,900,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,986,900,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_78B1FE0A2ECC, https://asof.is/claim/clm_78B1FE0A2ECC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_78B1FE0A2ECC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_600A80B3AFE0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_B8F364B1BB32","predicate":"quarterly_operating_income","value":"1,138,100,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,138,100,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_B8F364B1BB32, https://asof.is/claim/clm_B8F364B1BB32, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm.","url":"https://asof.is/claim/clm_B8F364B1BB32","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3B40C30B5BFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-05"}},{"id":"clm_B7B98F7F000A","predicate":"shares_outstanding","value":"254,034,190 shares","valid_from":"2026-02-06","valid_to":"2026-04-30","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 254,034,190 shares\", as of 2026-02-06 (until 2026-04-30). Claim clm_B7B98F7F000A, https://asof.is/claim/clm_B7B98F7F000A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_B7B98F7F000A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EA3BCAE7F8D0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_0090178AE4A5","predicate":"total_assets","value":"25,643,000,000 United States dollar","valid_from":"2025-12-31","valid_to":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 25,643,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_0090178AE4A5, https://asof.is/claim/clm_0090178AE4A5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_0090178AE4A5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_263F86EB65D1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_08B6F6FEE28A","predicate":"operating_income","value":"4,173,300,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 4,173,300,000 United States dollar\", as of 2025-12-31. Claim clm_08B6F6FEE28A, https://asof.is/claim/clm_08B6F6FEE28A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_08B6F6FEE28A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_335F6E7CE9CE","predicate":"total_equity","value":"18,665,800,000 United States dollar","valid_from":"2025-12-31","valid_to":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 18,665,800,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_335F6E7CE9CE, https://asof.is/claim/clm_335F6E7CE9CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_335F6E7CE9CE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0F975664C00F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_406C31565DD9","predicate":"net_income","value":"3,953,200,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 3,953,200,000 United States dollar\", as of 2025-12-31. Claim clm_406C31565DD9, https://asof.is/claim/clm_406C31565DD9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_406C31565DD9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_B151EC07FDAE","predicate":"revenue","value":"12,001,300,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 12,001,300,000 United States dollar\", as of 2025-12-31. Claim clm_B151EC07FDAE, https://asof.is/claim/clm_B151EC07FDAE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_B151EC07FDAE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_B4475729CD2A","predicate":"cash_and_equivalents","value":"5,084,800,000 United States dollar","valid_from":"2025-12-31","valid_to":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 5,084,800,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_B4475729CD2A, https://asof.is/claim/clm_B4475729CD2A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_B4475729CD2A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_379D75861ABB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-13"}},{"id":"clm_663C199EF289","predicate":"shares_outstanding","value":"253,718,831 shares","valid_from":"2025-10-31","valid_to":"2026-02-06","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,718,831 shares\", as of 2025-10-31 (until 2026-02-06). Claim clm_663C199EF289, https://asof.is/claim/clm_663C199EF289, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_663C199EF289","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B7B98F7F000A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_1E5EC8CA7B8E","predicate":"total_equity","value":"17,318,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 17,318,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_1E5EC8CA7B8E, https://asof.is/claim/clm_1E5EC8CA7B8E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_1E5EC8CA7B8E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_335F6E7CE9CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_2FB43E38D7CC","predicate":"cash_and_equivalents","value":"4,939,600,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,939,600,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_2FB43E38D7CC, https://asof.is/claim/clm_2FB43E38D7CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FB43E38D7CC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B4475729CD2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_2FE795B3AF8B","predicate":"quarterly_net_income","value":"1,082,900,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,082,900,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2FE795B3AF8B, https://asof.is/claim/clm_2FE795B3AF8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FE795B3AF8B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58ABF4712193","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7EF8A5505C22","predicate":"quarterly_operating_income","value":"1,186,200,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,186,200,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7EF8A5505C22, https://asof.is/claim/clm_7EF8A5505C22, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_7EF8A5505C22","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B8F364B1BB32","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_8AB184162D82","predicate":"quarterly_revenue","value":"3,076,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,076,400,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8AB184162D82, https://asof.is/claim/clm_8AB184162D82, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_8AB184162D82","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78B1FE0A2ECC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_D95598CEB876","predicate":"total_assets","value":"24,862,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 24,862,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D95598CEB876, https://asof.is/claim/clm_D95598CEB876, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_D95598CEB876","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0090178AE4A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_ABBFFDB9DFAC","predicate":"shares_outstanding","value":"256,390,651 shares","valid_from":"2025-07-31","valid_to":"2025-10-31","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,390,651 shares\", as of 2025-07-31 (until 2025-10-31). Claim clm_ABBFFDB9DFAC, https://asof.is/claim/clm_ABBFFDB9DFAC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_ABBFFDB9DFAC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_663C199EF289","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_3F4C3A8A99D1","predicate":"cash_and_equivalents","value":"4,972,200,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,972,200,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_3F4C3A8A99D1, https://asof.is/claim/clm_3F4C3A8A99D1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_3F4C3A8A99D1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2FB43E38D7CC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_68305CEE2495","predicate":"total_assets","value":"24,036,700,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 24,036,700,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_68305CEE2495, https://asof.is/claim/clm_68305CEE2495, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_68305CEE2495","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D95598CEB876","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_9B7DD75E016B","predicate":"quarterly_revenue","value":"2,964,700,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,964,700,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_9B7DD75E016B, https://asof.is/claim/clm_9B7DD75E016B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_9B7DD75E016B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8AB184162D82","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_C2590A2F1C6C","predicate":"quarterly_net_income","value":"1,032,900,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,032,900,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_C2590A2F1C6C, https://asof.is/claim/clm_C2590A2F1C6C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_C2590A2F1C6C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2FE795B3AF8B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_D44D3849A57A","predicate":"total_equity","value":"17,175,400,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 17,175,400,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_D44D3849A57A, https://asof.is/claim/clm_D44D3849A57A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_D44D3849A57A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E5EC8CA7B8E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_E417E8C56F51","predicate":"quarterly_operating_income","value":"1,151,100,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,151,100,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_E417E8C56F51, https://asof.is/claim/clm_E417E8C56F51, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm.","url":"https://asof.is/claim/clm_E417E8C56F51","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7EF8A5505C22","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-05"}},{"id":"clm_7659E4652BD8","predicate":"shares_outstanding","value":"256,797,187 shares","valid_from":"2025-04-30","valid_to":"2025-07-31","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,797,187 shares\", as of 2025-04-30 (until 2025-07-31). Claim clm_7659E4652BD8, https://asof.is/claim/clm_7659E4652BD8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_7659E4652BD8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ABBFFDB9DFAC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_030CF6670A5D","predicate":"total_equity","value":"16,496,300,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 16,496,300,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_030CF6670A5D, https://asof.is/claim/clm_030CF6670A5D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_030CF6670A5D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D44D3849A57A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_1EC0DE7E99A1","predicate":"quarterly_revenue","value":"2,770,200,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,770,200,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_1EC0DE7E99A1, https://asof.is/claim/clm_1EC0DE7E99A1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_1EC0DE7E99A1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9B7DD75E016B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_2C985FE30E22","predicate":"quarterly_operating_income","value":"630,100,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 630,100,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_2C985FE30E22, https://asof.is/claim/clm_2C985FE30E22, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_2C985FE30E22","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E417E8C56F51","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_AE9230AA7FE8","predicate":"total_assets","value":"22,880,500,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 22,880,500,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_AE9230AA7FE8, https://asof.is/claim/clm_AE9230AA7FE8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_AE9230AA7FE8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_68305CEE2495","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_D421BB040AD7","predicate":"cash_and_equivalents","value":"4,674,700,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,674,700,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_D421BB040AD7, https://asof.is/claim/clm_D421BB040AD7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_D421BB040AD7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3F4C3A8A99D1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_EDC8CDDAA243","predicate":"quarterly_net_income","value":"646,300,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 646,300,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_EDC8CDDAA243, https://asof.is/claim/clm_EDC8CDDAA243, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm.","url":"https://asof.is/claim/clm_EDC8CDDAA243","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C2590A2F1C6C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-06"}},{"id":"clm_30424A529FF7","predicate":"shares_outstanding","value":"256,789,869 shares","valid_from":"2025-02-07","valid_to":"2025-04-30","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,789,869 shares\", as of 2025-02-07 (until 2025-04-30). Claim clm_30424A529FF7, https://asof.is/claim/clm_30424A529FF7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_30424A529FF7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7659E4652BD8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_33A4466539E6","predicate":"operating_income","value":"-232,900,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -232,900,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_33A4466539E6, https://asof.is/claim/clm_33A4466539E6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_33A4466539E6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08B6F6FEE28A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_7036AF53899D","predicate":"cash_and_equivalents","value":"4,569,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-03-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,569,600,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_7036AF53899D, https://asof.is/claim/clm_7036AF53899D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_7036AF53899D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D421BB040AD7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_9011721F7C0D","predicate":"revenue","value":"11,020,100,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 11,020,100,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9011721F7C0D, https://asof.is/claim/clm_9011721F7C0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_9011721F7C0D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B151EC07FDAE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_B3A7B0C585DF","predicate":"net_income","value":"-535,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -535,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_B3A7B0C585DF, https://asof.is/claim/clm_B3A7B0C585DF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_B3A7B0C585DF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_406C31565DD9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_D2246EF67C62","predicate":"total_equity","value":"16,409,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-03-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 16,409,600,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_D2246EF67C62, https://asof.is/claim/clm_D2246EF67C62, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_D2246EF67C62","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_030CF6670A5D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_F4271585E734","predicate":"total_assets","value":"22,533,200,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-03-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 22,533,200,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_F4271585E734, https://asof.is/claim/clm_F4271585E734, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_F4271585E734","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AE9230AA7FE8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_CDAE1063FD1E","predicate":"shares_outstanding","value":"257,529,290 shares","valid_from":"2024-10-31","valid_to":"2025-02-07","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,529,290 shares\", as of 2024-10-31 (until 2025-02-07). Claim clm_CDAE1063FD1E, https://asof.is/claim/clm_CDAE1063FD1E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_CDAE1063FD1E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30424A529FF7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_00AA213A3D85","predicate":"total_equity","value":"15,630,900,000 United States dollar","valid_from":"2024-09-30","valid_to":"2024-12-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 15,630,900,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_00AA213A3D85, https://asof.is/claim/clm_00AA213A3D85, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_00AA213A3D85","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D2246EF67C62","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_17107958B9E8","predicate":"cash_and_equivalents","value":"5,239,200,000 United States dollar","valid_from":"2024-09-30","valid_to":"2024-12-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 5,239,200,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_17107958B9E8, https://asof.is/claim/clm_17107958B9E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_17107958B9E8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7036AF53899D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_6D94781B6A40","predicate":"total_assets","value":"22,240,200,000 United States dollar","valid_from":"2024-09-30","valid_to":"2024-12-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 22,240,200,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_6D94781B6A40, https://asof.is/claim/clm_6D94781B6A40, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_6D94781B6A40","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F4271585E734","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_85558B741195","predicate":"quarterly_revenue","value":"2,771,900,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,771,900,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_85558B741195, https://asof.is/claim/clm_85558B741195, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_85558B741195","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1EC0DE7E99A1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_8EC7750600BF","predicate":"quarterly_operating_income","value":"1,116,300,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,116,300,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_8EC7750600BF, https://asof.is/claim/clm_8EC7750600BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_8EC7750600BF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C985FE30E22","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_E844FD7AD190","predicate":"quarterly_net_income","value":"1,045,400,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,045,400,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_E844FD7AD190, https://asof.is/claim/clm_E844FD7AD190, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm.","url":"https://asof.is/claim/clm_E844FD7AD190","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EDC8CDDAA243","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-05"}},{"id":"clm_2E5075D7DBE3","predicate":"shares_outstanding","value":"258,102,203 shares","valid_from":"2024-07-31","valid_to":"2024-10-31","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 258,102,203 shares\", as of 2024-07-31 (until 2024-10-31). Claim clm_2E5075D7DBE3, https://asof.is/claim/clm_2E5075D7DBE3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_2E5075D7DBE3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CDAE1063FD1E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_3C97D5DB5816","predicate":"quarterly_operating_income","value":"-3,514,700,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -3,514,700,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_3C97D5DB5816, https://asof.is/claim/clm_3C97D5DB5816, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_3C97D5DB5816","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8EC7750600BF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_91183B1230B5","predicate":"total_assets","value":"20,132,100,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 20,132,100,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_91183B1230B5, https://asof.is/claim/clm_91183B1230B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_91183B1230B5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D94781B6A40","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_99B3D838F073","predicate":"quarterly_revenue","value":"2,645,600,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,645,600,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_99B3D838F073, https://asof.is/claim/clm_99B3D838F073, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_99B3D838F073","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_85558B741195","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_B131D7103BCE","predicate":"quarterly_net_income","value":"-3,593,600,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -3,593,600,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_B131D7103BCE, https://asof.is/claim/clm_B131D7103BCE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_B131D7103BCE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E844FD7AD190","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_C4593DB240D3","predicate":"cash_and_equivalents","value":"4,580,100,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,580,100,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_C4593DB240D3, https://asof.is/claim/clm_C4593DB240D3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_C4593DB240D3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_17107958B9E8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_D1FB9551C69B","predicate":"total_equity","value":"14,774,700,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 14,774,700,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_D1FB9551C69B, https://asof.is/claim/clm_D1FB9551C69B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm.","url":"https://asof.is/claim/clm_D1FB9551C69B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_00AA213A3D85","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-02"}},{"id":"clm_7CB6DBDB3720","predicate":"shares_outstanding","value":"258,053,387 shares","valid_from":"2024-04-30","valid_to":"2024-07-31","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 258,053,387 shares\", as of 2024-04-30 (until 2024-07-31). Claim clm_7CB6DBDB3720, https://asof.is/claim/clm_7CB6DBDB3720, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_7CB6DBDB3720","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2E5075D7DBE3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_4B154EA0AEAE","predicate":"agreement","value":"Alpine Immune Sciences, Inc.","valid_from":"2024-04-10","valid_to":null,"published":"2024-04-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals agreement: Alpine Immune Sciences, Inc.\", as of 2024-04-10. Claim clm_4B154EA0AEAE, https://asof.is/claim/clm_4B154EA0AEAE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm.","url":"https://asof.is/claim/clm_4B154EA0AEAE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2024-04-11T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into","url":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm"}},{"id":"clm_33B55A456707","predicate":"quarterly_net_income","value":"1,099,600,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,099,600,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_33B55A456707, https://asof.is/claim/clm_33B55A456707, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_33B55A456707","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B131D7103BCE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_3F0C247C527A","predicate":"total_equity","value":"18,546,600,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 18,546,600,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_3F0C247C527A, https://asof.is/claim/clm_3F0C247C527A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_3F0C247C527A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D1FB9551C69B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_40945582F02C","predicate":"quarterly_revenue","value":"2,690,600,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,690,600,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_40945582F02C, https://asof.is/claim/clm_40945582F02C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_40945582F02C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_99B3D838F073","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_472C99A37BC6","predicate":"quarterly_operating_income","value":"1,139,500,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,139,500,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_472C99A37BC6, https://asof.is/claim/clm_472C99A37BC6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_472C99A37BC6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3C97D5DB5816","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_BA38CFEB0E56","predicate":"cash_and_equivalents","value":"9,158,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 9,158,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_BA38CFEB0E56, https://asof.is/claim/clm_BA38CFEB0E56, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_BA38CFEB0E56","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C4593DB240D3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_E4FE15D6C00A","predicate":"total_assets","value":"23,917,400,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 23,917,400,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_E4FE15D6C00A, https://asof.is/claim/clm_E4FE15D6C00A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm.","url":"https://asof.is/claim/clm_E4FE15D6C00A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_91183B1230B5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-07"}},{"id":"clm_1BAB99487696","predicate":"shares_outstanding","value":"258,307,816 shares","valid_from":"2024-02-09","valid_to":"2024-04-30","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 258,307,816 shares\", as of 2024-02-09 (until 2024-04-30). Claim clm_1BAB99487696, https://asof.is/claim/clm_1BAB99487696, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_1BAB99487696","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7CB6DBDB3720","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_4295FD965DBB","predicate":"total_assets","value":"22,730,200,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-03-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 22,730,200,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_4295FD965DBB, https://asof.is/claim/clm_4295FD965DBB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_4295FD965DBB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E4FE15D6C00A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_6755CB60586A","predicate":"revenue","value":"9,869,200,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 9,869,200,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_6755CB60586A, https://asof.is/claim/clm_6755CB60586A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_6755CB60586A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9011721F7C0D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_89548106AA99","predicate":"total_equity","value":"17,580,400,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-03-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 17,580,400,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_89548106AA99, https://asof.is/claim/clm_89548106AA99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_89548106AA99","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3F0C247C527A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_CEBE7B1AF903","predicate":"cash_and_equivalents","value":"10,369,100,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-03-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 10,369,100,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_CEBE7B1AF903, https://asof.is/claim/clm_CEBE7B1AF903, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_CEBE7B1AF903","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA38CFEB0E56","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_DD75AE2A6FF1","predicate":"net_income","value":"3,619,600,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 3,619,600,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_DD75AE2A6FF1, https://asof.is/claim/clm_DD75AE2A6FF1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_DD75AE2A6FF1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B3A7B0C585DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_EDF03CE5BDB7","predicate":"operating_income","value":"3,832,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 3,832,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_EDF03CE5BDB7, https://asof.is/claim/clm_EDF03CE5BDB7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm.","url":"https://asof.is/claim/clm_EDF03CE5BDB7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_33A4466539E6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/0000875320-24-000062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-15"}},{"id":"clm_63DBD5A352EB","predicate":"shares_outstanding","value":"257,683,184 shares","valid_from":"2023-10-31","valid_to":"2024-02-09","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,683,184 shares\", as of 2023-10-31 (until 2024-02-09). Claim clm_63DBD5A352EB, https://asof.is/claim/clm_63DBD5A352EB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_63DBD5A352EB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1BAB99487696","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_25F0B0F08F89","predicate":"quarterly_revenue","value":"2,483,500,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,483,500,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_25F0B0F08F89, https://asof.is/claim/clm_25F0B0F08F89, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_25F0B0F08F89","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_40945582F02C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_3876937046B3","predicate":"cash_and_equivalents","value":"11,110,200,000 United States dollar","valid_from":"2023-09-30","valid_to":"2023-12-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 11,110,200,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_3876937046B3, https://asof.is/claim/clm_3876937046B3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_3876937046B3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CEBE7B1AF903","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_78BFE90ACA99","predicate":"quarterly_net_income","value":"1,035,300,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,035,300,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_78BFE90ACA99, https://asof.is/claim/clm_78BFE90ACA99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_78BFE90ACA99","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_33B55A456707","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_7E2CD975D5FB","predicate":"total_equity","value":"16,512,800,000 United States dollar","valid_from":"2023-09-30","valid_to":"2023-12-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 16,512,800,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_7E2CD975D5FB, https://asof.is/claim/clm_7E2CD975D5FB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_7E2CD975D5FB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_89548106AA99","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_9193F0BF1A10","predicate":"total_assets","value":"21,726,200,000 United States dollar","valid_from":"2023-09-30","valid_to":"2023-12-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 21,726,200,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_9193F0BF1A10, https://asof.is/claim/clm_9193F0BF1A10, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_9193F0BF1A10","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4295FD965DBB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_BE04B4442DA0","predicate":"quarterly_operating_income","value":"1,038,100,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,038,100,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_BE04B4442DA0, https://asof.is/claim/clm_BE04B4442DA0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm.","url":"https://asof.is/claim/clm_BE04B4442DA0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_472C99A37BC6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_AF5A88F5634C","predicate":"shares_outstanding","value":"258,094,815 shares","valid_from":"2023-07-31","valid_to":"2023-10-31","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 258,094,815 shares\", as of 2023-07-31 (until 2023-10-31). Claim clm_AF5A88F5634C, https://asof.is/claim/clm_AF5A88F5634C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_AF5A88F5634C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_63DBD5A352EB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_12CF2E7419A7","predicate":"quarterly_revenue","value":"2,493,200,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,493,200,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_12CF2E7419A7, https://asof.is/claim/clm_12CF2E7419A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_12CF2E7419A7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_25F0B0F08F89","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_351DD5011D1D","predicate":"total_assets","value":"20,349,200,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 20,349,200,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_351DD5011D1D, https://asof.is/claim/clm_351DD5011D1D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_351DD5011D1D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9193F0BF1A10","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_641582E9BBA4","predicate":"quarterly_operating_income","value":"1,026,400,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,026,400,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_641582E9BBA4, https://asof.is/claim/clm_641582E9BBA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_641582E9BBA4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BE04B4442DA0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_87BE0FC8B08C","predicate":"quarterly_net_income","value":"915,700,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 915,700,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_87BE0FC8B08C, https://asof.is/claim/clm_87BE0FC8B08C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_87BE0FC8B08C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78BFE90ACA99","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_B62228AD3B5C","predicate":"total_equity","value":"15,470,200,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 15,470,200,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_B62228AD3B5C, https://asof.is/claim/clm_B62228AD3B5C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_B62228AD3B5C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7E2CD975D5FB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_D4ECC6686864","predicate":"cash_and_equivalents","value":"10,151,100,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 10,151,100,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_D4ECC6686864, https://asof.is/claim/clm_D4ECC6686864, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm.","url":"https://asof.is/claim/clm_D4ECC6686864","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3876937046B3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-02"}},{"id":"clm_D7E4C28F5ECB","predicate":"shares_outstanding","value":"257,551,600 shares","valid_from":"2023-04-25","valid_to":"2023-07-31","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,551,600 shares\", as of 2023-04-25 (until 2023-07-31). Claim clm_D7E4C28F5ECB, https://asof.is/claim/clm_D7E4C28F5ECB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_D7E4C28F5ECB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AF5A88F5634C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_259DCABF6218","predicate":"total_equity","value":"14,432,300,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 14,432,300,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_259DCABF6218, https://asof.is/claim/clm_259DCABF6218, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_259DCABF6218","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B62228AD3B5C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_4D9C12DA102E","predicate":"quarterly_operating_income","value":"779,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 779,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_4D9C12DA102E, https://asof.is/claim/clm_4D9C12DA102E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_4D9C12DA102E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_641582E9BBA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_56F24DCACD81","predicate":"quarterly_revenue","value":"2,374,800,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,374,800,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_56F24DCACD81, https://asof.is/claim/clm_56F24DCACD81, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_56F24DCACD81","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12CF2E7419A7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_CCC1584CC243","predicate":"quarterly_net_income","value":"699,800,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 699,800,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_CCC1584CC243, https://asof.is/claim/clm_CCC1584CC243, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_CCC1584CC243","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_87BE0FC8B08C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_DA9B9E142C37","predicate":"cash_and_equivalents","value":"9,289,900,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 9,289,900,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_DA9B9E142C37, https://asof.is/claim/clm_DA9B9E142C37, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_DA9B9E142C37","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D4ECC6686864","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_FF4FA49D5268","predicate":"total_assets","value":"18,974,200,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 18,974,200,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_FF4FA49D5268, https://asof.is/claim/clm_FF4FA49D5268, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm.","url":"https://asof.is/claim/clm_FF4FA49D5268","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_351DD5011D1D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-02"}},{"id":"clm_3C5FD882584C","predicate":"shares_outstanding","value":"257,091,441 shares","valid_from":"2023-01-31","valid_to":"2023-04-25","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,091,441 shares\", as of 2023-01-31 (until 2023-04-25). Claim clm_3C5FD882584C, https://asof.is/claim/clm_3C5FD882584C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_3C5FD882584C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D7E4C28F5ECB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_1B7C3640D846","predicate":"net_income","value":"3,322,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 3,322,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_1B7C3640D846, https://asof.is/claim/clm_1B7C3640D846, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_1B7C3640D846","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DD75AE2A6FF1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_63A9B4EA0EFC","predicate":"cash_and_equivalents","value":"10,504,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-03-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 10,504,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_63A9B4EA0EFC, https://asof.is/claim/clm_63A9B4EA0EFC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_63A9B4EA0EFC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DA9B9E142C37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_6D580D76E517","predicate":"total_equity","value":"13,912,700,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-03-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 13,912,700,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_6D580D76E517, https://asof.is/claim/clm_6D580D76E517, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_6D580D76E517","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_259DCABF6218","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_9F22DDDCD1C9","predicate":"total_assets","value":"18,150,900,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-03-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 18,150,900,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_9F22DDDCD1C9, https://asof.is/claim/clm_9F22DDDCD1C9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_9F22DDDCD1C9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FF4FA49D5268","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_AC7CF3A293FF","predicate":"revenue","value":"8,930,700,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 8,930,700,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_AC7CF3A293FF, https://asof.is/claim/clm_AC7CF3A293FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_AC7CF3A293FF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6755CB60586A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_EA4DD24E67F5","predicate":"operating_income","value":"4,307,400,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 4,307,400,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_EA4DD24E67F5, https://asof.is/claim/clm_EA4DD24E67F5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm.","url":"https://asof.is/claim/clm_EA4DD24E67F5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EDF03CE5BDB7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/0000875320-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-10"}},{"id":"clm_07E003F90843","predicate":"shares_outstanding","value":"256,691,452 shares","valid_from":"2022-10-21","valid_to":"2023-01-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,691,452 shares\", as of 2022-10-21 (until 2023-01-31). Claim clm_07E003F90843, https://asof.is/claim/clm_07E003F90843, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_07E003F90843","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3C5FD882584C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_0BD6127815F8","predicate":"cash_and_equivalents","value":"9,171,500,000 United States dollar","valid_from":"2022-09-30","valid_to":"2022-12-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 9,171,500,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_0BD6127815F8, https://asof.is/claim/clm_0BD6127815F8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_0BD6127815F8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_63A9B4EA0EFC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_2C70611C367D","predicate":"total_assets","value":"16,706,400,000 United States dollar","valid_from":"2022-09-30","valid_to":"2022-12-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 16,706,400,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_2C70611C367D, https://asof.is/claim/clm_2C70611C367D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_2C70611C367D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9F22DDDCD1C9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_4BC06D9A5911","predicate":"quarterly_net_income","value":"930,500,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 930,500,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_4BC06D9A5911, https://asof.is/claim/clm_4BC06D9A5911, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_4BC06D9A5911","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CCC1584CC243","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_61A9104D30AD","predicate":"total_equity","value":"13,029,600,000 United States dollar","valid_from":"2022-09-30","valid_to":"2022-12-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 13,029,600,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_61A9104D30AD, https://asof.is/claim/clm_61A9104D30AD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_61A9104D30AD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D580D76E517","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_A07370340B6C","predicate":"quarterly_revenue","value":"2,334,300,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,334,300,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_A07370340B6C, https://asof.is/claim/clm_A07370340B6C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_A07370340B6C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56F24DCACD81","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_E6727C1C16C9","predicate":"quarterly_operating_income","value":"1,126,700,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,126,700,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_E6727C1C16C9, https://asof.is/claim/clm_E6727C1C16C9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm.","url":"https://asof.is/claim/clm_E6727C1C16C9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4D9C12DA102E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-10-28"}},{"id":"clm_09C3E31B05ED","predicate":"shares_outstanding","value":"256,459,482 shares","valid_from":"2022-07-29","valid_to":"2022-10-21","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,459,482 shares\", as of 2022-07-29 (until 2022-10-21). Claim clm_09C3E31B05ED, https://asof.is/claim/clm_09C3E31B05ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_09C3E31B05ED","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_07E003F90843","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_09D1A8C06700","predicate":"total_assets","value":"15,582,200,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 15,582,200,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_09D1A8C06700, https://asof.is/claim/clm_09D1A8C06700, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_09D1A8C06700","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C70611C367D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_203BAAA42E77","predicate":"quarterly_net_income","value":"810,500,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 810,500,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_203BAAA42E77, https://asof.is/claim/clm_203BAAA42E77, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_203BAAA42E77","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4BC06D9A5911","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_2EBAE376F4A3","predicate":"cash_and_equivalents","value":"8,702,200,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 8,702,200,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_2EBAE376F4A3, https://asof.is/claim/clm_2EBAE376F4A3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_2EBAE376F4A3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0BD6127815F8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_53E6658C91B5","predicate":"total_equity","value":"11,933,500,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 11,933,500,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_53E6658C91B5, https://asof.is/claim/clm_53E6658C91B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_53E6658C91B5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_61A9104D30AD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_5B1D0BBCD832","predicate":"quarterly_operating_income","value":"1,106,300,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,106,300,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_5B1D0BBCD832, https://asof.is/claim/clm_5B1D0BBCD832, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_5B1D0BBCD832","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E6727C1C16C9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_F084A45C1F3A","predicate":"quarterly_revenue","value":"2,196,200,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,196,200,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_F084A45C1F3A, https://asof.is/claim/clm_F084A45C1F3A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm.","url":"https://asof.is/claim/clm_F084A45C1F3A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A07370340B6C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2022, filed 2022-08-05"}},{"id":"clm_CD985C968363","predicate":"shares_outstanding","value":"255,755,961 shares","valid_from":"2022-04-29","valid_to":"2022-07-29","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 255,755,961 shares\", as of 2022-04-29 (until 2022-07-29). Claim clm_CD985C968363, https://asof.is/claim/clm_CD985C968363, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_CD985C968363","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_09C3E31B05ED","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_243DDF043D62","predicate":"quarterly_net_income","value":"762,100,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 762,100,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_243DDF043D62, https://asof.is/claim/clm_243DDF043D62, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_243DDF043D62","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_203BAAA42E77","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_2A24B9B7FC69","predicate":"quarterly_operating_income","value":"1,040,900,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,040,900,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_2A24B9B7FC69, https://asof.is/claim/clm_2A24B9B7FC69, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_2A24B9B7FC69","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B1D0BBCD832","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_318FD2D6E763","predicate":"total_equity","value":"10,907,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 10,907,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_318FD2D6E763, https://asof.is/claim/clm_318FD2D6E763, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_318FD2D6E763","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_53E6658C91B5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_47EA232B8F9C","predicate":"quarterly_revenue","value":"2,097,500,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 2,097,500,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_47EA232B8F9C, https://asof.is/claim/clm_47EA232B8F9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_47EA232B8F9C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F084A45C1F3A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_AAF7A5074870","predicate":"cash_and_equivalents","value":"7,600,100,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 7,600,100,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_AAF7A5074870, https://asof.is/claim/clm_AAF7A5074870, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_AAF7A5074870","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2EBAE376F4A3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_AEC6A8645EE2","predicate":"total_assets","value":"14,256,100,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 14,256,100,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_AEC6A8645EE2, https://asof.is/claim/clm_AEC6A8645EE2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_AEC6A8645EE2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_09D1A8C06700","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_CF81367A05A7","predicate":"quarterly_research_and_development","value":"603,100,000 United States dollar","valid_from":"2022-03-31","valid_to":null,"published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 603,100,000 United States dollar\", as of 2022-03-31. Claim clm_CF81367A05A7, https://asof.is/claim/clm_CF81367A05A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_CF81367A05A7","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_075B175EC177","predicate":"shares_outstanding","value":"254,576,691 shares","valid_from":"2022-01-31","valid_to":"2022-04-29","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 254,576,691 shares\", as of 2022-01-31 (until 2022-04-29). Claim clm_075B175EC177, https://asof.is/claim/clm_075B175EC177, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_075B175EC177","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CD985C968363","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_054958897891","predicate":"revenue","value":"7,574,400,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 7,574,400,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_054958897891, https://asof.is/claim/clm_054958897891, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_054958897891","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AC7CF3A293FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_1E5426FCEFF5","predicate":"total_equity","value":"10,100,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-03-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 10,100,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_1E5426FCEFF5, https://asof.is/claim/clm_1E5426FCEFF5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_1E5426FCEFF5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_318FD2D6E763","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_883D81B67C94","predicate":"total_assets","value":"13,432,500,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-03-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 13,432,500,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_883D81B67C94, https://asof.is/claim/clm_883D81B67C94, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_883D81B67C94","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AEC6A8645EE2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_A31B2D7AAD7A","predicate":"research_and_development","value":"3,051,100,000 United States dollar","valid_from":"2021-12-31","valid_to":null,"published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 3,051,100,000 United States dollar\", as of 2021-12-31. Claim clm_A31B2D7AAD7A, https://asof.is/claim/clm_A31B2D7AAD7A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_A31B2D7AAD7A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_A982731934E0","predicate":"cash_and_equivalents","value":"6,795,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-03-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 6,795,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_A982731934E0, https://asof.is/claim/clm_A982731934E0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_A982731934E0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AAF7A5074870","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_DB3896AB26E8","predicate":"operating_income","value":"2,782,100,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 2,782,100,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_DB3896AB26E8, https://asof.is/claim/clm_DB3896AB26E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_DB3896AB26E8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EA4DD24E67F5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_F3A2B9FC81F1","predicate":"net_income","value":"2,342,100,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 2,342,100,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_F3A2B9FC81F1, https://asof.is/claim/clm_F3A2B9FC81F1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_F3A2B9FC81F1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B7C3640D846","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_02288182B0BB","predicate":"shares_outstanding","value":"254,251,938 shares","valid_from":"2021-10-29","valid_to":"2022-01-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 254,251,938 shares\", as of 2021-10-29 (until 2022-01-31). Claim clm_02288182B0BB, https://asof.is/claim/clm_02288182B0BB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_02288182B0BB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_075B175EC177","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_1CB49C635F67","predicate":"quarterly_operating_income","value":"1,054,512,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,054,512,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_1CB49C635F67, https://asof.is/claim/clm_1CB49C635F67, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_1CB49C635F67","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A24B9B7FC69","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_6BB57BAD5620","predicate":"quarterly_revenue","value":"1,984,164,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,984,164,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_6BB57BAD5620, https://asof.is/claim/clm_6BB57BAD5620, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_6BB57BAD5620","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_47EA232B8F9C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_86D501AB2F5C","predicate":"quarterly_research_and_development","value":"493,751,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 493,751,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_86D501AB2F5C, https://asof.is/claim/clm_86D501AB2F5C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_86D501AB2F5C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CF81367A05A7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_90424EB08D26","predicate":"total_assets","value":"12,618,745,000 United States dollar","valid_from":"2021-09-30","valid_to":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 12,618,745,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_90424EB08D26, https://asof.is/claim/clm_90424EB08D26, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_90424EB08D26","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_883D81B67C94","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_94A2F9498133","predicate":"quarterly_net_income","value":"851,928,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 851,928,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_94A2F9498133, https://asof.is/claim/clm_94A2F9498133, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_94A2F9498133","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_243DDF043D62","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_B630EC176E52","predicate":"total_equity","value":"9,530,708,000 United States dollar","valid_from":"2021-09-30","valid_to":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 9,530,708,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_B630EC176E52, https://asof.is/claim/clm_B630EC176E52, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_B630EC176E52","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E5426FCEFF5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_CC12F522D151","predicate":"cash_and_equivalents","value":"6,275,698,000 United States dollar","valid_from":"2021-09-30","valid_to":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 6,275,698,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_CC12F522D151, https://asof.is/claim/clm_CC12F522D151, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm.","url":"https://asof.is/claim/clm_CC12F522D151","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A982731934E0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_B929FA328F8E","predicate":"shares_outstanding","value":"259,428,394 shares","valid_from":"2021-07-23","valid_to":"2021-10-29","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 259,428,394 shares\", as of 2021-07-23 (until 2021-10-29). Claim clm_B929FA328F8E, https://asof.is/claim/clm_B929FA328F8E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_B929FA328F8E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_02288182B0BB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_1F15DBA70DE0","predicate":"quarterly_operating_income","value":"-37,961,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -37,961,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_1F15DBA70DE0, https://asof.is/claim/clm_1F15DBA70DE0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_1F15DBA70DE0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1CB49C635F67","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_4F89C70F30F6","predicate":"quarterly_net_income","value":"66,924,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 66,924,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_4F89C70F30F6, https://asof.is/claim/clm_4F89C70F30F6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_4F89C70F30F6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_94A2F9498133","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_84A1E26AC5B8","predicate":"cash_and_equivalents","value":"6,063,678,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 6,063,678,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_84A1E26AC5B8, https://asof.is/claim/clm_84A1E26AC5B8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_84A1E26AC5B8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CC12F522D151","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_A83B0E7547F1","predicate":"total_equity","value":"9,196,396,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 9,196,396,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_A83B0E7547F1, https://asof.is/claim/clm_A83B0E7547F1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_A83B0E7547F1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B630EC176E52","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_BA95AEDBE337","predicate":"quarterly_revenue","value":"1,793,370,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,793,370,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_BA95AEDBE337, https://asof.is/claim/clm_BA95AEDBE337, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_BA95AEDBE337","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6BB57BAD5620","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_DC884CD97A0D","predicate":"quarterly_research_and_development","value":"1,407,090,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 1,407,090,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_DC884CD97A0D, https://asof.is/claim/clm_DC884CD97A0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_DC884CD97A0D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_86D501AB2F5C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_E7CFB5DF9247","predicate":"total_assets","value":"12,221,686,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 12,221,686,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_E7CFB5DF9247, https://asof.is/claim/clm_E7CFB5DF9247, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm.","url":"https://asof.is/claim/clm_E7CFB5DF9247","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_90424EB08D26","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-07-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-07-30"}},{"id":"clm_BF1FDA0B7CEF","predicate":"shares_outstanding","value":"258,865,671 shares","valid_from":"2021-04-22","valid_to":"2021-07-23","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 258,865,671 shares\", as of 2021-04-22 (until 2021-07-23). Claim clm_BF1FDA0B7CEF, https://asof.is/claim/clm_BF1FDA0B7CEF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_BF1FDA0B7CEF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B929FA328F8E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_05E33637AD96","predicate":"quarterly_revenue","value":"1,724,305,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,724,305,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_05E33637AD96, https://asof.is/claim/clm_05E33637AD96, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_05E33637AD96","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA95AEDBE337","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_934E3BFFB8E5","predicate":"total_assets","value":"12,115,059,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 12,115,059,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_934E3BFFB8E5, https://asof.is/claim/clm_934E3BFFB8E5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_934E3BFFB8E5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E7CFB5DF9247","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_A498CCC0EE53","predicate":"total_equity","value":"8,980,254,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 8,980,254,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_A498CCC0EE53, https://asof.is/claim/clm_A498CCC0EE53, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_A498CCC0EE53","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A83B0E7547F1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_C212C614D9A6","predicate":"quarterly_operating_income","value":"887,826,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 887,826,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_C212C614D9A6, https://asof.is/claim/clm_C212C614D9A6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_C212C614D9A6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1F15DBA70DE0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_D8AA2809B20A","predicate":"quarterly_net_income","value":"653,138,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 653,138,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_D8AA2809B20A, https://asof.is/claim/clm_D8AA2809B20A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_D8AA2809B20A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4F89C70F30F6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_E30E4F36DF29","predicate":"cash_and_equivalents","value":"6,304,330,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 6,304,330,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_E30E4F36DF29, https://asof.is/claim/clm_E30E4F36DF29, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_E30E4F36DF29","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_84A1E26AC5B8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_E4E066FF8D42","predicate":"quarterly_research_and_development","value":"455,973,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 455,973,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_E4E066FF8D42, https://asof.is/claim/clm_E4E066FF8D42, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_E4E066FF8D42","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DC884CD97A0D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_DB51B55830F5","predicate":"shares_outstanding","value":"259,960,062 shares","valid_from":"2021-01-31","valid_to":"2021-04-22","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 259,960,062 shares\", as of 2021-01-31 (until 2021-04-22). Claim clm_DB51B55830F5, https://asof.is/claim/clm_DB51B55830F5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_DB51B55830F5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BF1FDA0B7CEF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_0A0A75CC866D","predicate":"cash_and_equivalents","value":"5,988,187,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-03-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 5,988,187,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_0A0A75CC866D, https://asof.is/claim/clm_0A0A75CC866D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_0A0A75CC866D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E30E4F36DF29","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_12C888060D24","predicate":"total_equity","value":"8,686,800,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-03-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 8,686,800,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_12C888060D24, https://asof.is/claim/clm_12C888060D24, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_12C888060D24","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A498CCC0EE53","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_227207794AE5","predicate":"operating_income","value":"2,856,290,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 2,856,290,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_227207794AE5, https://asof.is/claim/clm_227207794AE5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_227207794AE5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DB3896AB26E8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_4E727A17F6D8","predicate":"research_and_development","value":"1,829,537,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 1,829,537,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_4E727A17F6D8, https://asof.is/claim/clm_4E727A17F6D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_4E727A17F6D8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A31B2D7AAD7A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_710D5BB40195","predicate":"revenue","value":"6,205,683,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 6,205,683,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_710D5BB40195, https://asof.is/claim/clm_710D5BB40195, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_710D5BB40195","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_054958897891","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_79102BFD0743","predicate":"net_income","value":"2,711,647,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 2,711,647,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_79102BFD0743, https://asof.is/claim/clm_79102BFD0743, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_79102BFD0743","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F3A2B9FC81F1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_C7952DDAD12A","predicate":"total_assets","value":"11,751,808,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-03-31","published":"2021-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 11,751,808,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_C7952DDAD12A, https://asof.is/claim/clm_C7952DDAD12A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm.","url":"https://asof.is/claim/clm_C7952DDAD12A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_934E3BFFB8E5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000006/0000875320-21-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-11"}},{"id":"clm_5240C50AF834","predicate":"shares_outstanding","value":"260,037,894 shares","valid_from":"2020-10-23","valid_to":"2021-01-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 260,037,894 shares\", as of 2020-10-23 (until 2021-01-31). Claim clm_5240C50AF834, https://asof.is/claim/clm_5240C50AF834, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_5240C50AF834","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DB51B55830F5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_12837A3657DA","predicate":"total_assets","value":"11,301,633,000 United States dollar","valid_from":"2020-09-30","valid_to":"2020-12-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 11,301,633,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_12837A3657DA, https://asof.is/claim/clm_12837A3657DA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_12837A3657DA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C7952DDAD12A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_4C3B1A02B828","predicate":"quarterly_operating_income","value":"672,241,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 672,241,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_4C3B1A02B828, https://asof.is/claim/clm_4C3B1A02B828, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_4C3B1A02B828","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C212C614D9A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_69B23FF91BEB","predicate":"cash_and_equivalents","value":"5,358,087,000 United States dollar","valid_from":"2020-09-30","valid_to":"2020-12-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 5,358,087,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_69B23FF91BEB, https://asof.is/claim/clm_69B23FF91BEB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_69B23FF91BEB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0A0A75CC866D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_8C6FF5B4800E","predicate":"quarterly_research_and_development","value":"493,497,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 493,497,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_8C6FF5B4800E, https://asof.is/claim/clm_8C6FF5B4800E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_8C6FF5B4800E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E4E066FF8D42","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_9E3B341B6DD1","predicate":"total_equity","value":"8,133,473,000 United States dollar","valid_from":"2020-09-30","valid_to":"2020-12-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 8,133,473,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_9E3B341B6DD1, https://asof.is/claim/clm_9E3B341B6DD1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_9E3B341B6DD1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12C888060D24","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_B82BAA2538E3","predicate":"quarterly_net_income","value":"667,434,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 667,434,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_B82BAA2538E3, https://asof.is/claim/clm_B82BAA2538E3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_B82BAA2538E3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D8AA2809B20A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_D38659C12AE8","predicate":"quarterly_revenue","value":"1,538,271,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,538,271,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_D38659C12AE8, https://asof.is/claim/clm_D38659C12AE8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_D38659C12AE8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_05E33637AD96","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_9BAB61679F38","predicate":"shares_outstanding","value":"260,467,334 shares","valid_from":"2020-07-23","valid_to":"2020-10-23","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 260,467,334 shares\", as of 2020-07-23 (until 2020-10-23). Claim clm_9BAB61679F38, https://asof.is/claim/clm_9BAB61679F38, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_9BAB61679F38","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5240C50AF834","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_194411381C8C","predicate":"total_assets","value":"10,216,367,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 10,216,367,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_194411381C8C, https://asof.is/claim/clm_194411381C8C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_194411381C8C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12837A3657DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_6915B8D4ABB5","predicate":"cash_and_equivalents","value":"4,831,332,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,831,332,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_6915B8D4ABB5, https://asof.is/claim/clm_6915B8D4ABB5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_6915B8D4ABB5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_69B23FF91BEB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_92B502813AA4","predicate":"quarterly_research_and_development","value":"420,928,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 420,928,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_92B502813AA4, https://asof.is/claim/clm_92B502813AA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_92B502813AA4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8C6FF5B4800E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_BF61DD66F463","predicate":"total_equity","value":"7,519,242,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 7,519,242,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_BF61DD66F463, https://asof.is/claim/clm_BF61DD66F463, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_BF61DD66F463","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9E3B341B6DD1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_CBAB0AE654C4","predicate":"quarterly_net_income","value":"837,270,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 837,270,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_CBAB0AE654C4, https://asof.is/claim/clm_CBAB0AE654C4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_CBAB0AE654C4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B82BAA2538E3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_EE20986F8F62","predicate":"quarterly_revenue","value":"1,524,485,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,524,485,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_EE20986F8F62, https://asof.is/claim/clm_EE20986F8F62, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_EE20986F8F62","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D38659C12AE8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_FE5D60C65052","predicate":"quarterly_operating_income","value":"718,033,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 718,033,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_FE5D60C65052, https://asof.is/claim/clm_FE5D60C65052, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm.","url":"https://asof.is/claim/clm_FE5D60C65052","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4C3B1A02B828","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-31"}},{"id":"clm_987CBFB7A223","predicate":"shares_outstanding","value":"259,276,709 shares","valid_from":"2020-04-24","valid_to":"2020-07-23","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 259,276,709 shares\", as of 2020-04-24 (until 2020-07-23). Claim clm_987CBFB7A223, https://asof.is/claim/clm_987CBFB7A223, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_987CBFB7A223","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9BAB61679F38","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_5AE1EF5CC196","predicate":"quarterly_research_and_development","value":"448,528,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 448,528,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_5AE1EF5CC196, https://asof.is/claim/clm_5AE1EF5CC196, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_5AE1EF5CC196","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_92B502813AA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_98EA8D3ED9D1","predicate":"quarterly_net_income","value":"602,753,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 602,753,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_98EA8D3ED9D1, https://asof.is/claim/clm_98EA8D3ED9D1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_98EA8D3ED9D1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CBAB0AE654C4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_AC9CCBAF0908","predicate":"cash_and_equivalents","value":"3,593,412,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 3,593,412,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_AC9CCBAF0908, https://asof.is/claim/clm_AC9CCBAF0908, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_AC9CCBAF0908","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6915B8D4ABB5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_C020ABBFE645","predicate":"total_assets","value":"8,893,201,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 8,893,201,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_C020ABBFE645, https://asof.is/claim/clm_C020ABBFE645, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_C020ABBFE645","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_194411381C8C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_C1525E494CB5","predicate":"total_equity","value":"6,461,654,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 6,461,654,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_C1525E494CB5, https://asof.is/claim/clm_C1525E494CB5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm.","url":"https://asof.is/claim/clm_C1525E494CB5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BF61DD66F463","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-04-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-04-30"}},{"id":"clm_EB1B0B642262","predicate":"quarterly_operating_income","value":"720,224,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 720,224,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_EB1B0B642262, https://asof.is/claim/clm_EB1B0B642262, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_EB1B0B642262","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FE5D60C65052","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_ED12A2E330B4","predicate":"quarterly_revenue","value":"1,515,107,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 1,515,107,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_ED12A2E330B4, https://asof.is/claim/clm_ED12A2E330B4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm.","url":"https://asof.is/claim/clm_ED12A2E330B4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EE20986F8F62","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2020, filed 2020-05-01"}},{"id":"clm_B0DC25435A02","predicate":"shares_outstanding","value":"259,268,593 shares","valid_from":"2020-01-31","valid_to":"2020-04-24","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 259,268,593 shares\", as of 2020-01-31 (until 2020-04-24). Claim clm_B0DC25435A02, https://asof.is/claim/clm_B0DC25435A02, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_B0DC25435A02","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_987CBFB7A223","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_05A793B89218","predicate":"operating_income","value":"1,197,566,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 1,197,566,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_05A793B89218, https://asof.is/claim/clm_05A793B89218, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_05A793B89218","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_227207794AE5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_2E4E3E5F618D","predicate":"total_equity","value":"6,085,200,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-03-31","published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 6,085,200,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_2E4E3E5F618D, https://asof.is/claim/clm_2E4E3E5F618D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_2E4E3E5F618D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C1525E494CB5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_4875DCC74B8B","predicate":"research_and_development","value":"1,754,540,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 1,754,540,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_4875DCC74B8B, https://asof.is/claim/clm_4875DCC74B8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_4875DCC74B8B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4E727A17F6D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_8D8808029B98","predicate":"cash_and_equivalents","value":"3,109,322,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-03-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 3,109,322,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_8D8808029B98, https://asof.is/claim/clm_8D8808029B98, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_8D8808029B98","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AC9CCBAF0908","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_8E39CFC66249","predicate":"total_assets","value":"8,318,465,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-03-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 8,318,465,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_8E39CFC66249, https://asof.is/claim/clm_8E39CFC66249, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_8E39CFC66249","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C020ABBFE645","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_98E5E59F6D9E","predicate":"revenue","value":"4,162,821,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 4,162,821,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_98E5E59F6D9E, https://asof.is/claim/clm_98E5E59F6D9E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_98E5E59F6D9E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_710D5BB40195","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_FE5B5CF4FB84","predicate":"net_income","value":"1,176,810,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 1,176,810,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_FE5B5CF4FB84, https://asof.is/claim/clm_FE5B5CF4FB84, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm.","url":"https://asof.is/claim/clm_FE5B5CF4FB84","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_79102BFD0743","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_F6BD01886FBB","predicate":"shares_outstanding","value":"257,149,588 shares","valid_from":"2019-10-18","valid_to":"2020-01-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,149,588 shares\", as of 2019-10-18 (until 2020-01-31). Claim clm_F6BD01886FBB, https://asof.is/claim/clm_F6BD01886FBB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_F6BD01886FBB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B0DC25435A02","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_01DE6C70A804","predicate":"quarterly_revenue","value":"949,828,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 949,828,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_01DE6C70A804, https://asof.is/claim/clm_01DE6C70A804, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_01DE6C70A804","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ED12A2E330B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_606AE4761405","predicate":"total_assets","value":"7,514,553,000 United States dollar","valid_from":"2019-09-30","valid_to":"2019-12-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 7,514,553,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_606AE4761405, https://asof.is/claim/clm_606AE4761405, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_606AE4761405","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8E39CFC66249","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_63C6CFD02CA4","predicate":"quarterly_operating_income","value":"99,333,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 99,333,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_63C6CFD02CA4, https://asof.is/claim/clm_63C6CFD02CA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_63C6CFD02CA4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EB1B0B642262","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_713E0D0A2043","predicate":"cash_and_equivalents","value":"3,397,941,000 United States dollar","valid_from":"2019-09-30","valid_to":"2019-12-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 3,397,941,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_713E0D0A2043, https://asof.is/claim/clm_713E0D0A2043, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_713E0D0A2043","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8D8808029B98","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_81C047352B0D","predicate":"quarterly_net_income","value":"57,518,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 57,518,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_81C047352B0D, https://asof.is/claim/clm_81C047352B0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_81C047352B0D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_98EA8D3ED9D1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_DBBB2E7ADFB1","predicate":"total_equity","value":"5,253,394,000 United States dollar","valid_from":"2019-09-30","valid_to":"2019-12-31","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 5,253,394,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_DBBB2E7ADFB1, https://asof.is/claim/clm_DBBB2E7ADFB1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_DBBB2E7ADFB1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2E4E3E5F618D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_E4FC8BA4267A","predicate":"quarterly_research_and_development","value":"555,948,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 555,948,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_E4FC8BA4267A, https://asof.is/claim/clm_E4FC8BA4267A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm.","url":"https://asof.is/claim/clm_E4FC8BA4267A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5AE1EF5CC196","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-10-31"}},{"id":"clm_1AA1A71F7141","predicate":"shares_outstanding","value":"257,035,443 shares","valid_from":"2019-07-26","valid_to":"2019-10-18","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 257,035,443 shares\", as of 2019-07-26 (until 2019-10-18). Claim clm_1AA1A71F7141, https://asof.is/claim/clm_1AA1A71F7141, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_1AA1A71F7141","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F6BD01886FBB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_0B97F438BFA4","predicate":"total_assets","value":"7,033,471,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 7,033,471,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_0B97F438BFA4, https://asof.is/claim/clm_0B97F438BFA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_0B97F438BFA4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_606AE4761405","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_3837B5FA4621","predicate":"quarterly_operating_income","value":"269,960,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 269,960,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_3837B5FA4621, https://asof.is/claim/clm_3837B5FA4621, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_3837B5FA4621","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_63C6CFD02CA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_391AC2F64417","predicate":"quarterly_net_income","value":"267,427,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 267,427,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_391AC2F64417, https://asof.is/claim/clm_391AC2F64417, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_391AC2F64417","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_81C047352B0D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_6053DA9FFA3A","predicate":"quarterly_research_and_development","value":"379,091,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 379,091,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_6053DA9FFA3A, https://asof.is/claim/clm_6053DA9FFA3A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_6053DA9FFA3A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E4FC8BA4267A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_73E5227A4A27","predicate":"cash_and_equivalents","value":"3,294,684,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 3,294,684,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_73E5227A4A27, https://asof.is/claim/clm_73E5227A4A27, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_73E5227A4A27","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_713E0D0A2043","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_CDABAE46C981","predicate":"quarterly_revenue","value":"941,293,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 941,293,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_CDABAE46C981, https://asof.is/claim/clm_CDABAE46C981, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm.","url":"https://asof.is/claim/clm_CDABAE46C981","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_01DE6C70A804","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2019, filed 2019-08-01"}},{"id":"clm_DD7CA9ADDF1C","predicate":"total_equity","value":"5,069,965,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2020-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 5,069,965,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_DD7CA9ADDF1C, https://asof.is/claim/clm_DD7CA9ADDF1C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm.","url":"https://asof.is/claim/clm_DD7CA9ADDF1C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DBBB2E7ADFB1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-30"}},{"id":"clm_9180A1508E64","predicate":"shares_outstanding","value":"256,121,360 shares","valid_from":"2019-04-24","valid_to":"2019-07-26","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 256,121,360 shares\", as of 2019-04-24 (until 2019-07-26). Claim clm_9180A1508E64, https://asof.is/claim/clm_9180A1508E64, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_9180A1508E64","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1AA1A71F7141","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_19FEE797F4E7","predicate":"total_equity","value":"4,723,313,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 4,723,313,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_19FEE797F4E7, https://asof.is/claim/clm_19FEE797F4E7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_19FEE797F4E7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DD7CA9ADDF1C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_1A5BF9CE8A15","predicate":"quarterly_research_and_development","value":"339,490,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 339,490,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_1A5BF9CE8A15, https://asof.is/claim/clm_1A5BF9CE8A15, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_1A5BF9CE8A15","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6053DA9FFA3A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_3E7B3994881E","predicate":"quarterly_revenue","value":"858,435,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 858,435,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_3E7B3994881E, https://asof.is/claim/clm_3E7B3994881E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_3E7B3994881E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CDABAE46C981","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_3ECBB5B268CD","predicate":"total_assets","value":"6,543,114,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 6,543,114,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_3ECBB5B268CD, https://asof.is/claim/clm_3ECBB5B268CD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_3ECBB5B268CD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0B97F438BFA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_6686B23D1227","predicate":"quarterly_operating_income","value":"276,808,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 276,808,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_6686B23D1227, https://asof.is/claim/clm_6686B23D1227, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_6686B23D1227","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3837B5FA4621","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_AA625CEFE3E2","predicate":"cash_and_equivalents","value":"2,893,885,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 2,893,885,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_AA625CEFE3E2, https://asof.is/claim/clm_AA625CEFE3E2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_AA625CEFE3E2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_73E5227A4A27","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_BFDA13517B9A","predicate":"quarterly_net_income","value":"268,631,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 268,631,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_BFDA13517B9A, https://asof.is/claim/clm_BFDA13517B9A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm.","url":"https://asof.is/claim/clm_BFDA13517B9A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_391AC2F64417","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"id":"clm_2DB9804ECA5E","predicate":"shares_outstanding","value":"255,656,889 shares","valid_from":"2019-01-31","valid_to":"2019-04-24","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 255,656,889 shares\", as of 2019-01-31 (until 2019-04-24). Claim clm_2DB9804ECA5E, https://asof.is/claim/clm_2DB9804ECA5E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_2DB9804ECA5E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9180A1508E64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_E43D77EF5B44","predicate":"total_assets","value":"6,261,958,000 United States dollar","valid_from":"2019-01-01","valid_to":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 6,261,958,000 United States dollar\", as of 2019-01-01 (until 2019-03-31). Claim clm_E43D77EF5B44, https://asof.is/claim/clm_E43D77EF5B44, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_E43D77EF5B44","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3ECBB5B268CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532020000007/0000875320-20-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-13"}},{"id":"clm_30D3676BC4AE","predicate":"operating_income","value":"635,150,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 635,150,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_30D3676BC4AE, https://asof.is/claim/clm_30D3676BC4AE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_30D3676BC4AE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_05A793B89218","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_38ED4A3E086C","predicate":"total_equity","value":"4,435,203,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 4,435,203,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_38ED4A3E086C, https://asof.is/claim/clm_38ED4A3E086C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_38ED4A3E086C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_19FEE797F4E7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_9652C550528A","predicate":"revenue","value":"3,047,597,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 3,047,597,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_9652C550528A, https://asof.is/claim/clm_9652C550528A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_9652C550528A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_98E5E59F6D9E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_D3A2B88BD1F9","predicate":"net_income","value":"2,096,896,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 2,096,896,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_D3A2B88BD1F9, https://asof.is/claim/clm_D3A2B88BD1F9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_D3A2B88BD1F9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FE5B5CF4FB84","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_EF7099311C58","predicate":"research_and_development","value":"1,416,476,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 1,416,476,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_EF7099311C58, https://asof.is/claim/clm_EF7099311C58, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_EF7099311C58","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4875DCC74B8B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_F36C4149DAE9","predicate":"cash_and_equivalents","value":"2,650,134,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 2,650,134,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_F36C4149DAE9, https://asof.is/claim/clm_F36C4149DAE9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_F36C4149DAE9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AA625CEFE3E2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-13"}},{"id":"clm_D3864179769E","predicate":"shares_outstanding","value":"255,558,035 shares","valid_from":"2018-10-19","valid_to":"2019-01-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 255,558,035 shares\", as of 2018-10-19 (until 2019-01-31). Claim clm_D3864179769E, https://asof.is/claim/clm_D3864179769E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_D3864179769E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2DB9804ECA5E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_346AA350FC6D","predicate":"quarterly_net_income","value":"128,746,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 128,746,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_346AA350FC6D, https://asof.is/claim/clm_346AA350FC6D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_346AA350FC6D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BFDA13517B9A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_815A8BEADE9D","predicate":"total_equity","value":"2,906,116,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 2,906,116,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_815A8BEADE9D, https://asof.is/claim/clm_815A8BEADE9D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_815A8BEADE9D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_38ED4A3E086C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_8E2ABC809D39","predicate":"quarterly_revenue","value":"784,535,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 784,535,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_8E2ABC809D39, https://asof.is/claim/clm_8E2ABC809D39, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_8E2ABC809D39","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3E7B3994881E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_8F818D2E2F7B","predicate":"cash_and_equivalents","value":"2,478,302,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 2,478,302,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_8F818D2E2F7B, https://asof.is/claim/clm_8F818D2E2F7B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_8F818D2E2F7B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F36C4149DAE9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_C2CDDE4D143F","predicate":"total_assets","value":"4,620,840,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 4,620,840,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_C2CDDE4D143F, https://asof.is/claim/clm_C2CDDE4D143F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_C2CDDE4D143F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E43D77EF5B44","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_C5F9C8D7CC95","predicate":"quarterly_research_and_development","value":"330,510,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 330,510,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_C5F9C8D7CC95, https://asof.is/claim/clm_C5F9C8D7CC95, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_C5F9C8D7CC95","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1A5BF9CE8A15","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_D6C88602928F","predicate":"quarterly_operating_income","value":"205,649,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 205,649,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_D6C88602928F, https://asof.is/claim/clm_D6C88602928F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm.","url":"https://asof.is/claim/clm_D6C88602928F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6686B23D1227","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-10-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-25"}},{"id":"clm_A2CE75CC8517","predicate":"shares_outstanding","value":"255,559,939 shares","valid_from":"2018-07-20","valid_to":"2018-10-19","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 255,559,939 shares\", as of 2018-07-20 (until 2018-10-19). Claim clm_A2CE75CC8517, https://asof.is/claim/clm_A2CE75CC8517, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_A2CE75CC8517","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D3864179769E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_0E72F2D69F41","predicate":"quarterly_net_income","value":"207,360,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 207,360,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_0E72F2D69F41, https://asof.is/claim/clm_0E72F2D69F41, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_0E72F2D69F41","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_346AA350FC6D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_30C87D2C1CBD","predicate":"total_assets","value":"4,335,386,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 4,335,386,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_30C87D2C1CBD, https://asof.is/claim/clm_30C87D2C1CBD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_30C87D2C1CBD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C2CDDE4D143F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_61C96CE7DB96","predicate":"quarterly_operating_income","value":"172,878,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 172,878,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_61C96CE7DB96, https://asof.is/claim/clm_61C96CE7DB96, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_61C96CE7DB96","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D6C88602928F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_75860C5404D3","predicate":"quarterly_research_and_development","value":"337,532,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 337,532,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_75860C5404D3, https://asof.is/claim/clm_75860C5404D3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_75860C5404D3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C5F9C8D7CC95","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_7A545FD3F361","predicate":"quarterly_revenue","value":"752,157,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 752,157,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_7A545FD3F361, https://asof.is/claim/clm_7A545FD3F361, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_7A545FD3F361","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8E2ABC809D39","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_ADD73E1FB943","predicate":"cash_and_equivalents","value":"2,145,359,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 2,145,359,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_ADD73E1FB943, https://asof.is/claim/clm_ADD73E1FB943, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_ADD73E1FB943","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8F818D2E2F7B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_BDF180B6AD97","predicate":"total_equity","value":"2,686,228,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 2,686,228,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_BDF180B6AD97, https://asof.is/claim/clm_BDF180B6AD97, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm.","url":"https://asof.is/claim/clm_BDF180B6AD97","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_815A8BEADE9D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-07-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-07-26"}},{"id":"clm_D91AA7148A23","predicate":"shares_outstanding","value":"254,830,232 shares","valid_from":"2018-04-20","valid_to":"2018-07-20","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 254,830,232 shares\", as of 2018-04-20 (until 2018-07-20). Claim clm_D91AA7148A23, https://asof.is/claim/clm_D91AA7148A23, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_D91AA7148A23","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A2CE75CC8517","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_0D1ACE4B2058","predicate":"quarterly_research_and_development","value":"310,553,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 310,553,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_0D1ACE4B2058, https://asof.is/claim/clm_0D1ACE4B2058, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_0D1ACE4B2058","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_75860C5404D3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_4E19B710DABA","predicate":"total_assets","value":"3,952,974,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 3,952,974,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_4E19B710DABA, https://asof.is/claim/clm_4E19B710DABA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_4E19B710DABA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30C87D2C1CBD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_66E56361C26E","predicate":"quarterly_revenue","value":"640,799,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 640,799,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_66E56361C26E, https://asof.is/claim/clm_66E56361C26E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_66E56361C26E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7A545FD3F361","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_6AE5A6A85AD2","predicate":"quarterly_net_income","value":"210,263,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 210,263,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_6AE5A6A85AD2, https://asof.is/claim/clm_6AE5A6A85AD2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_6AE5A6A85AD2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E72F2D69F41","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_765AB85FE8D8","predicate":"cash_and_equivalents","value":"1,995,893,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,995,893,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_765AB85FE8D8, https://asof.is/claim/clm_765AB85FE8D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_765AB85FE8D8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ADD73E1FB943","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_A620E2C8FB71","predicate":"quarterly_operating_income","value":"128,901,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 128,901,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_A620E2C8FB71, https://asof.is/claim/clm_A620E2C8FB71, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_A620E2C8FB71","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_61C96CE7DB96","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_A9DE66326560","predicate":"total_equity","value":"2,401,056,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 2,401,056,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_A9DE66326560, https://asof.is/claim/clm_A9DE66326560, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm.","url":"https://asof.is/claim/clm_A9DE66326560","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BDF180B6AD97","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-04-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-04-27"}},{"id":"clm_0E283F15F605","predicate":"shares_outstanding","value":"253,891,984 shares","valid_from":"2018-01-31","valid_to":"2018-04-20","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,891,984 shares\", as of 2018-01-31 (until 2018-04-20). Claim clm_0E283F15F605, https://asof.is/claim/clm_0E283F15F605, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_0E283F15F605","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D91AA7148A23","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_0222BA7D9859","predicate":"total_assets","value":"3,546,014,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 3,546,014,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_0222BA7D9859, https://asof.is/claim/clm_0222BA7D9859, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm.","url":"https://asof.is/claim/clm_0222BA7D9859","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4E19B710DABA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532019000006/0000875320-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-13T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_03E98C0A4208","predicate":"operating_income","value":"123,243,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 123,243,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_03E98C0A4208, https://asof.is/claim/clm_03E98C0A4208, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_03E98C0A4208","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30D3676BC4AE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_76C027BAF647","predicate":"cash_and_equivalents","value":"1,665,412,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,665,412,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_76C027BAF647, https://asof.is/claim/clm_76C027BAF647, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_76C027BAF647","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_765AB85FE8D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_88AABB0F5900","predicate":"revenue","value":"2,488,652,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 2,488,652,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_88AABB0F5900, https://asof.is/claim/clm_88AABB0F5900, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_88AABB0F5900","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9652C550528A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_A0081165ACC0","predicate":"total_equity","value":"2,028,579,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 2,028,579,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_A0081165ACC0, https://asof.is/claim/clm_A0081165ACC0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_A0081165ACC0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A9DE66326560","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_C5B2018B6129","predicate":"research_and_development","value":"1,324,625,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 1,324,625,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_C5B2018B6129, https://asof.is/claim/clm_C5B2018B6129, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_C5B2018B6129","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF7099311C58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_EAA313C25D3D","predicate":"net_income","value":"263,484,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 263,484,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_EAA313C25D3D, https://asof.is/claim/clm_EAA313C25D3D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm.","url":"https://asof.is/claim/clm_EAA313C25D3D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D3A2B88BD1F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/0000875320-18-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-15T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-15"}},{"id":"clm_40905FFA2E58","predicate":"shares_outstanding","value":"252,902,848 shares","valid_from":"2017-10-20","valid_to":"2018-01-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 252,902,848 shares\", as of 2017-10-20 (until 2018-01-31). Claim clm_40905FFA2E58, https://asof.is/claim/clm_40905FFA2E58, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_40905FFA2E58","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E283F15F605","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_1A65A038D644","predicate":"quarterly_operating_income","value":"-326,043,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -326,043,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_1A65A038D644, https://asof.is/claim/clm_1A65A038D644, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_1A65A038D644","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A620E2C8FB71","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_2F530EB00B1B","predicate":"total_equity","value":"1,791,077,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,791,077,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_2F530EB00B1B, https://asof.is/claim/clm_2F530EB00B1B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_2F530EB00B1B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A0081165ACC0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_5202D9005278","predicate":"quarterly_research_and_development","value":"454,947,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 454,947,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_5202D9005278, https://asof.is/claim/clm_5202D9005278, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_5202D9005278","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0D1ACE4B2058","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_72B030278F2C","predicate":"total_assets","value":"3,198,325,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 3,198,325,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_72B030278F2C, https://asof.is/claim/clm_72B030278F2C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_72B030278F2C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0222BA7D9859","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_751B22F9EDDB","predicate":"cash_and_equivalents","value":"1,384,966,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,384,966,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_751B22F9EDDB, https://asof.is/claim/clm_751B22F9EDDB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_751B22F9EDDB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76C027BAF647","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_933F26C8B388","predicate":"quarterly_revenue","value":"578,165,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 578,165,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_933F26C8B388, https://asof.is/claim/clm_933F26C8B388, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_933F26C8B388","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_66E56361C26E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_ED246483C6AB","predicate":"quarterly_net_income","value":"-102,952,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -102,952,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_ED246483C6AB, https://asof.is/claim/clm_ED246483C6AB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm.","url":"https://asof.is/claim/clm_ED246483C6AB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6AE5A6A85AD2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-10-30"}},{"id":"clm_096340916E85","predicate":"shares_outstanding","value":"252,118,869 shares","valid_from":"2017-07-21","valid_to":"2017-10-20","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 252,118,869 shares\", as of 2017-07-21 (until 2017-10-20). Claim clm_096340916E85, https://asof.is/claim/clm_096340916E85, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_096340916E85","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_40905FFA2E58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_41E7A07E4BD9","predicate":"cash_and_equivalents","value":"1,223,130,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,223,130,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_41E7A07E4BD9, https://asof.is/claim/clm_41E7A07E4BD9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_41E7A07E4BD9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_751B22F9EDDB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_4FCE9FD3FD98","predicate":"quarterly_operating_income","value":"52,707,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 52,707,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_4FCE9FD3FD98, https://asof.is/claim/clm_4FCE9FD3FD98, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_4FCE9FD3FD98","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1A65A038D644","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_8500F4409507","predicate":"total_equity","value":"1,671,273,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,671,273,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_8500F4409507, https://asof.is/claim/clm_8500F4409507, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_8500F4409507","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2F530EB00B1B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_B48FA71C174F","predicate":"quarterly_research_and_development","value":"289,451,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 289,451,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_B48FA71C174F, https://asof.is/claim/clm_B48FA71C174F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_B48FA71C174F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5202D9005278","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_DAC478AD397E","predicate":"quarterly_net_income","value":"17,996,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 17,996,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_DAC478AD397E, https://asof.is/claim/clm_DAC478AD397E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_DAC478AD397E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ED246483C6AB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_E2CB6E1CCE2A","predicate":"total_assets","value":"3,285,594,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 3,285,594,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_E2CB6E1CCE2A, https://asof.is/claim/clm_E2CB6E1CCE2A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_E2CB6E1CCE2A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_72B030278F2C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_F514C594F662","predicate":"quarterly_revenue","value":"544,135,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 544,135,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_F514C594F662, https://asof.is/claim/clm_F514C594F662, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm.","url":"https://asof.is/claim/clm_F514C594F662","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_933F26C8B388","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-07-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2017, filed 2017-07-28"}},{"id":"clm_AC9B824300B5","predicate":"shares_outstanding","value":"249,068,782 shares","valid_from":"2017-04-21","valid_to":"2017-07-21","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 249,068,782 shares\", as of 2017-04-21 (until 2017-07-21). Claim clm_AC9B824300B5, https://asof.is/claim/clm_AC9B824300B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_AC9B824300B5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_096340916E85","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_218F213EBD5A","predicate":"total_assets","value":"2,946,703,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,946,703,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_218F213EBD5A, https://asof.is/claim/clm_218F213EBD5A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_218F213EBD5A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2CB6E1CCE2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_37FE3BC729D9","predicate":"quarterly_operating_income","value":"270,842,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 270,842,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_37FE3BC729D9, https://asof.is/claim/clm_37FE3BC729D9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_37FE3BC729D9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4FCE9FD3FD98","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_7D8A031A80DB","predicate":"quarterly_revenue","value":"714,718,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 714,718,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_7D8A031A80DB, https://asof.is/claim/clm_7D8A031A80DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_7D8A031A80DB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F514C594F662","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_90976FB1C473","predicate":"quarterly_research_and_development","value":"273,563,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 273,563,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_90976FB1C473, https://asof.is/claim/clm_90976FB1C473, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_90976FB1C473","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B48FA71C174F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_B3CDEA1413F9","predicate":"total_equity","value":"1,500,008,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,500,008,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_B3CDEA1413F9, https://asof.is/claim/clm_B3CDEA1413F9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_B3CDEA1413F9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8500F4409507","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_D5FCBE91D068","predicate":"cash_and_equivalents","value":"1,003,679,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,003,679,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_D5FCBE91D068, https://asof.is/claim/clm_D5FCBE91D068, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_D5FCBE91D068","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_41E7A07E4BD9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_EB70297A6910","predicate":"quarterly_net_income","value":"247,756,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 247,756,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_EB70297A6910, https://asof.is/claim/clm_EB70297A6910, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm.","url":"https://asof.is/claim/clm_EB70297A6910","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DAC478AD397E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-04-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-04-28"}},{"id":"clm_56628A376B7F","predicate":"shares_outstanding","value":"248,438,127 shares","valid_from":"2017-02-10","valid_to":"2017-04-21","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 248,438,127 shares\", as of 2017-02-10 (until 2017-04-21). Claim clm_56628A376B7F, https://asof.is/claim/clm_56628A376B7F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_56628A376B7F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AC9B824300B5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_070B60D12935","predicate":"research_and_development","value":"1,047,690,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 1,047,690,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_070B60D12935, https://asof.is/claim/clm_070B60D12935, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_070B60D12935","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C5B2018B6129","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_2BC71558F3C9","predicate":"net_income","value":"-112,052,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -112,052,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_2BC71558F3C9, https://asof.is/claim/clm_2BC71558F3C9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_2BC71558F3C9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EAA313C25D3D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_3048F4177FBD","predicate":"revenue","value":"1,702,177,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 1,702,177,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_3048F4177FBD, https://asof.is/claim/clm_3048F4177FBD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_3048F4177FBD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_88AABB0F5900","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_39A46EBA4944","predicate":"total_assets","value":"2,896,787,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,896,787,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_39A46EBA4944, https://asof.is/claim/clm_39A46EBA4944, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_39A46EBA4944","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_218F213EBD5A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_A595BC2C5630","predicate":"total_equity","value":"1,156,582,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,156,582,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_A595BC2C5630, https://asof.is/claim/clm_A595BC2C5630, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_A595BC2C5630","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B3CDEA1413F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_C74861030CDE","predicate":"operating_income","value":"9,936,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 9,936,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_C74861030CDE, https://asof.is/claim/clm_C74861030CDE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_C74861030CDE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_03E98C0A4208","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_DD9DC904D715","predicate":"cash_and_equivalents","value":"1,183,945,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 1,183,945,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_DD9DC904D715, https://asof.is/claim/clm_DD9DC904D715, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm.","url":"https://asof.is/claim/clm_DD9DC904D715","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D5FCBE91D068","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532017000017/0000875320-17-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-23"}},{"id":"clm_E95980D51DAA","predicate":"shares_outstanding","value":"248,033,389 shares","valid_from":"2016-10-21","valid_to":"2017-02-10","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 248,033,389 shares\", as of 2016-10-21 (until 2017-02-10). Claim clm_E95980D51DAA, https://asof.is/claim/clm_E95980D51DAA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_E95980D51DAA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56628A376B7F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_0B18EFEDD159","predicate":"cash_and_equivalents","value":"719,692,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 719,692,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_0B18EFEDD159, https://asof.is/claim/clm_0B18EFEDD159, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_0B18EFEDD159","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DD9DC904D715","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_26C5F13E4AFA","predicate":"total_equity","value":"1,021,546,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,021,546,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_26C5F13E4AFA, https://asof.is/claim/clm_26C5F13E4AFA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_26C5F13E4AFA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A595BC2C5630","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_3FA9F1E3CCFF","predicate":"total_assets","value":"2,609,641,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,609,641,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_3FA9F1E3CCFF, https://asof.is/claim/clm_3FA9F1E3CCFF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_3FA9F1E3CCFF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_39A46EBA4944","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_77AD1FA686BE","predicate":"quarterly_research_and_development","value":"272,370,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 272,370,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_77AD1FA686BE, https://asof.is/claim/clm_77AD1FA686BE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_77AD1FA686BE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_90976FB1C473","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_882D250549DB","predicate":"quarterly_revenue","value":"413,783,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 413,783,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_882D250549DB, https://asof.is/claim/clm_882D250549DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_882D250549DB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7D8A031A80DB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_E8FAE6590B2B","predicate":"quarterly_net_income","value":"-38,841,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -38,841,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_E8FAE6590B2B, https://asof.is/claim/clm_E8FAE6590B2B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_E8FAE6590B2B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EB70297A6910","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_FD2D956B4646","predicate":"quarterly_operating_income","value":"-18,727,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -18,727,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_FD2D956B4646, https://asof.is/claim/clm_FD2D956B4646, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm.","url":"https://asof.is/claim/clm_FD2D956B4646","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_37FE3BC729D9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-10-31"}},{"id":"clm_AAFEE05A628C","predicate":"shares_outstanding","value":"247,778,698 shares","valid_from":"2016-07-22","valid_to":"2016-10-21","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 247,778,698 shares\", as of 2016-07-22 (until 2016-10-21). Claim clm_AAFEE05A628C, https://asof.is/claim/clm_AAFEE05A628C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_AAFEE05A628C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E95980D51DAA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_0E60C94FDAC7","predicate":"total_assets","value":"2,548,982,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,548,982,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_0E60C94FDAC7, https://asof.is/claim/clm_0E60C94FDAC7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_0E60C94FDAC7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3FA9F1E3CCFF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_1C6CC599E968","predicate":"cash_and_equivalents","value":"605,866,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 605,866,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_1C6CC599E968, https://asof.is/claim/clm_1C6CC599E968, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_1C6CC599E968","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0B18EFEDD159","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_2228EE6A3A62","predicate":"quarterly_operating_income","value":"3,353,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 3,353,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_2228EE6A3A62, https://asof.is/claim/clm_2228EE6A3A62, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_2228EE6A3A62","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FD2D956B4646","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_3D46B58FF11A","predicate":"quarterly_revenue","value":"431,608,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 431,608,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_3D46B58FF11A, https://asof.is/claim/clm_3D46B58FF11A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_3D46B58FF11A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_882D250549DB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_6A661CF6BB52","predicate":"quarterly_net_income","value":"-64,525,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -64,525,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_6A661CF6BB52, https://asof.is/claim/clm_6A661CF6BB52, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_6A661CF6BB52","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E8FAE6590B2B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_C3B5C13564FF","predicate":"quarterly_research_and_development","value":"271,008,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 271,008,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_C3B5C13564FF, https://asof.is/claim/clm_C3B5C13564FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_C3B5C13564FF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_77AD1FA686BE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_E3F59624DB5A","predicate":"total_equity","value":"981,354,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 981,354,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_E3F59624DB5A, https://asof.is/claim/clm_E3F59624DB5A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm.","url":"https://asof.is/claim/clm_E3F59624DB5A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_26C5F13E4AFA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-01"}},{"id":"clm_184409A3DE47","predicate":"shares_outstanding","value":"247,349,864 shares","valid_from":"2016-04-20","valid_to":"2016-07-22","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 247,349,864 shares\", as of 2016-04-20 (until 2016-07-22). Claim clm_184409A3DE47, https://asof.is/claim/clm_184409A3DE47, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_184409A3DE47","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AAFEE05A628C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_08C42F082050","predicate":"quarterly_research_and_development","value":"255,860,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 255,860,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_08C42F082050, https://asof.is/claim/clm_08C42F082050, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_08C42F082050","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C3B5C13564FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_1114776585A3","predicate":"total_assets","value":"2,487,906,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,487,906,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_1114776585A3, https://asof.is/claim/clm_1114776585A3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_1114776585A3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E60C94FDAC7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_6D374A34EDA7","predicate":"quarterly_operating_income","value":"-14,330,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -14,330,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_6D374A34EDA7, https://asof.is/claim/clm_6D374A34EDA7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_6D374A34EDA7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2228EE6A3A62","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_70FFDCCAA48B","predicate":"cash_and_equivalents","value":"604,245,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 604,245,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_70FFDCCAA48B, https://asof.is/claim/clm_70FFDCCAA48B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_70FFDCCAA48B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1C6CC599E968","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_AB61E3D00C03","predicate":"total_equity","value":"957,079,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 957,079,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_AB61E3D00C03, https://asof.is/claim/clm_AB61E3D00C03, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_AB61E3D00C03","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E3F59624DB5A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_D1405FE577D0","predicate":"quarterly_revenue","value":"398,080,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 398,080,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_D1405FE577D0, https://asof.is/claim/clm_D1405FE577D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_D1405FE577D0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3D46B58FF11A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_D76BCB337804","predicate":"quarterly_net_income","value":"-41,631,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -41,631,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_D76BCB337804, https://asof.is/claim/clm_D76BCB337804, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm.","url":"https://asof.is/claim/clm_D76BCB337804","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A661CF6BB52","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-03"}},{"id":"clm_E922A99A9EA6","predicate":"shares_outstanding","value":"246,391,955 shares","valid_from":"2016-01-31","valid_to":"2016-04-20","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 246,391,955 shares\", as of 2016-01-31 (until 2016-04-20). Claim clm_E922A99A9EA6, https://asof.is/claim/clm_E922A99A9EA6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_E922A99A9EA6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_184409A3DE47","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_09536F600AFF","predicate":"research_and_development","value":"995,922,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 995,922,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_09536F600AFF, https://asof.is/claim/clm_09536F600AFF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_09536F600AFF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_070B60D12935","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_1B7DAA0B3049","predicate":"total_assets","value":"2,498,875,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,498,875,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_1B7DAA0B3049, https://asof.is/claim/clm_1B7DAA0B3049, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_1B7DAA0B3049","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1114776585A3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_3CC906E153DA","predicate":"net_income","value":"-556,334,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -556,334,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_3CC906E153DA, https://asof.is/claim/clm_3CC906E153DA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_3CC906E153DA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2BC71558F3C9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_B6F6CDFC9E0A","predicate":"operating_income","value":"-466,879,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -466,879,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_B6F6CDFC9E0A, https://asof.is/claim/clm_B6F6CDFC9E0A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_B6F6CDFC9E0A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C74861030CDE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_B9A0D3A94E4B","predicate":"revenue","value":"1,032,336,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 1,032,336,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_B9A0D3A94E4B, https://asof.is/claim/clm_B9A0D3A94E4B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_B9A0D3A94E4B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3048F4177FBD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_E053D1ED646F","predicate":"cash_and_equivalents","value":"714,768,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 714,768,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_E053D1ED646F, https://asof.is/claim/clm_E053D1ED646F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_E053D1ED646F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_70FFDCCAA48B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_F45B3CB0C752","predicate":"total_equity","value":"939,967,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 939,967,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_F45B3CB0C752, https://asof.is/claim/clm_F45B3CB0C752, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm.","url":"https://asof.is/claim/clm_F45B3CB0C752","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AB61E3D00C03","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532016000067/0000875320-16-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-16"}},{"id":"clm_A9C81118AB1C","predicate":"shares_outstanding","value":"245,717,286 shares","valid_from":"2015-10-23","valid_to":"2016-01-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 245,717,286 shares\", as of 2015-10-23 (until 2016-01-31). Claim clm_A9C81118AB1C, https://asof.is/claim/clm_A9C81118AB1C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_A9C81118AB1C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E922A99A9EA6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_60B4E50AFB70","predicate":"total_assets","value":"2,433,993,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,433,993,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_60B4E50AFB70, https://asof.is/claim/clm_60B4E50AFB70, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_60B4E50AFB70","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B7DAA0B3049","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_6E79D9B514B1","predicate":"quarterly_research_and_development","value":"246,284,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 246,284,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_6E79D9B514B1, https://asof.is/claim/clm_6E79D9B514B1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_6E79D9B514B1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08C42F082050","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_716BECC984E5","predicate":"quarterly_net_income","value":"-95,149,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -95,149,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_716BECC984E5, https://asof.is/claim/clm_716BECC984E5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_716BECC984E5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D76BCB337804","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_86562BC405C6","predicate":"quarterly_revenue","value":"309,816,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 309,816,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_86562BC405C6, https://asof.is/claim/clm_86562BC405C6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_86562BC405C6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D1405FE577D0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_979E4CDDAA4B","predicate":"total_equity","value":"922,147,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 922,147,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_979E4CDDAA4B, https://asof.is/claim/clm_979E4CDDAA4B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_979E4CDDAA4B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F45B3CB0C752","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_A645F319F190","predicate":"quarterly_operating_income","value":"-70,026,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -70,026,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_A645F319F190, https://asof.is/claim/clm_A645F319F190, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_A645F319F190","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D374A34EDA7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_D372DE4FDD99","predicate":"cash_and_equivalents","value":"756,250,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 756,250,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_D372DE4FDD99, https://asof.is/claim/clm_D372DE4FDD99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm.","url":"https://asof.is/claim/clm_D372DE4FDD99","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E053D1ED646F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-10-30"}},{"id":"clm_74711F790F20","predicate":"shares_outstanding","value":"244,655,527 shares","valid_from":"2015-07-24","valid_to":"2015-10-23","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 244,655,527 shares\", as of 2015-07-24 (until 2015-10-23). Claim clm_74711F790F20, https://asof.is/claim/clm_74711F790F20, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_74711F790F20","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A9C81118AB1C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_00535EE0B591","predicate":"quarterly_operating_income","value":"-171,164,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -171,164,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_00535EE0B591, https://asof.is/claim/clm_00535EE0B591, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_00535EE0B591","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A645F319F190","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_03E4A3140826","predicate":"quarterly_research_and_development","value":"223,858,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 223,858,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_03E4A3140826, https://asof.is/claim/clm_03E4A3140826, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_03E4A3140826","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6E79D9B514B1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_12232D5A6B98","predicate":"total_equity","value":"894,964,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 894,964,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_12232D5A6B98, https://asof.is/claim/clm_12232D5A6B98, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_12232D5A6B98","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_979E4CDDAA4B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_1EF267F21DD6","predicate":"cash_and_equivalents","value":"870,543,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 870,543,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_1EF267F21DD6, https://asof.is/claim/clm_1EF267F21DD6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_1EF267F21DD6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D372DE4FDD99","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_26173C591341","predicate":"quarterly_revenue","value":"166,076,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 166,076,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_26173C591341, https://asof.is/claim/clm_26173C591341, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_26173C591341","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_86562BC405C6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_82FAC17B63B7","predicate":"total_assets","value":"2,374,073,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,374,073,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_82FAC17B63B7, https://asof.is/claim/clm_82FAC17B63B7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_82FAC17B63B7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60B4E50AFB70","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_E074FD6EA019","predicate":"quarterly_net_income","value":"-188,848,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -188,848,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_E074FD6EA019, https://asof.is/claim/clm_E074FD6EA019, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm.","url":"https://asof.is/claim/clm_E074FD6EA019","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_716BECC984E5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"id":"clm_F2E292BAD47A","predicate":"shares_outstanding","value":"243,752,247 shares","valid_from":"2015-04-24","valid_to":"2015-07-24","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 243,752,247 shares\", as of 2015-04-24 (until 2015-07-24). Claim clm_F2E292BAD47A, https://asof.is/claim/clm_F2E292BAD47A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_F2E292BAD47A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_74711F790F20","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_2A57AC8A186B","predicate":"quarterly_research_and_development","value":"215,599,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 215,599,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_2A57AC8A186B, https://asof.is/claim/clm_2A57AC8A186B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_2A57AC8A186B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_03E4A3140826","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_33DE4ADFA95C","predicate":"total_equity","value":"976,458,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 976,458,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_33DE4ADFA95C, https://asof.is/claim/clm_33DE4ADFA95C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_33DE4ADFA95C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12232D5A6B98","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_3ADC1054C2B6","predicate":"quarterly_operating_income","value":"-171,985,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -171,985,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_3ADC1054C2B6, https://asof.is/claim/clm_3ADC1054C2B6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_3ADC1054C2B6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_00535EE0B591","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_64459540A52F","predicate":"quarterly_net_income","value":"-198,606,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -198,606,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_64459540A52F, https://asof.is/claim/clm_64459540A52F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_64459540A52F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E074FD6EA019","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_72E202E696DB","predicate":"quarterly_revenue","value":"138,509,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 138,509,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_72E202E696DB, https://asof.is/claim/clm_72E202E696DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_72E202E696DB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_26173C591341","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_D21E1EE854F6","predicate":"total_assets","value":"2,165,827,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,165,827,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_D21E1EE854F6, https://asof.is/claim/clm_D21E1EE854F6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_D21E1EE854F6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_82FAC17B63B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_ECB58BC2FBDB","predicate":"cash_and_equivalents","value":"664,879,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 664,879,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_ECB58BC2FBDB, https://asof.is/claim/clm_ECB58BC2FBDB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm.","url":"https://asof.is/claim/clm_ECB58BC2FBDB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1EF267F21DD6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-04"}},{"id":"clm_4142294B3920","predicate":"shares_outstanding","value":"242,088,884 shares","valid_from":"2015-01-31","valid_to":"2015-04-24","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 242,088,884 shares\", as of 2015-01-31 (until 2015-04-24). Claim clm_4142294B3920, https://asof.is/claim/clm_4142294B3920, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_4142294B3920","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F2E292BAD47A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_16DE270CBEB7","predicate":"total_equity","value":"1,075,006,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,075,006,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_16DE270CBEB7, https://asof.is/claim/clm_16DE270CBEB7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_16DE270CBEB7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_33DE4ADFA95C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_2F6A721A75E3","predicate":"research_and_development","value":"855,506,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 855,506,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_2F6A721A75E3, https://asof.is/claim/clm_2F6A721A75E3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_2F6A721A75E3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_09536F600AFF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_34CC74560F05","predicate":"total_assets","value":"2,334,679,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,334,679,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_34CC74560F05, https://asof.is/claim/clm_34CC74560F05, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_34CC74560F05","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D21E1EE854F6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_729B31AEC767","predicate":"operating_income","value":"-692,412,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -692,412,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_729B31AEC767, https://asof.is/claim/clm_729B31AEC767, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_729B31AEC767","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B6F6CDFC9E0A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_76E972477DD6","predicate":"revenue","value":"580,415,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 580,415,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_76E972477DD6, https://asof.is/claim/clm_76E972477DD6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_76E972477DD6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B9A0D3A94E4B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_C9477D430932","predicate":"cash_and_equivalents","value":"625,259,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 625,259,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_C9477D430932, https://asof.is/claim/clm_C9477D430932, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_C9477D430932","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ECB58BC2FBDB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_E0C813E29FDB","predicate":"net_income","value":"-738,555,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -738,555,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_E0C813E29FDB, https://asof.is/claim/clm_E0C813E29FDB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm.","url":"https://asof.is/claim/clm_E0C813E29FDB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3CC906E153DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532015000012/0000875320-15-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-13"}},{"id":"clm_479F66F00F16","predicate":"shares_outstanding","value":"240,521,809 shares","valid_from":"2014-10-31","valid_to":"2015-01-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 240,521,809 shares\", as of 2014-10-31 (until 2015-01-31). Claim clm_479F66F00F16, https://asof.is/claim/clm_479F66F00F16, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_479F66F00F16","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4142294B3920","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_230B3E2BC570","predicate":"quarterly_operating_income","value":"-142,203,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -142,203,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_230B3E2BC570, https://asof.is/claim/clm_230B3E2BC570, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_230B3E2BC570","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3ADC1054C2B6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_411488F61069","predicate":"quarterly_research_and_development","value":"190,939,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 190,939,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_411488F61069, https://asof.is/claim/clm_411488F61069, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_411488F61069","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A57AC8A186B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_6195F192CBDE","predicate":"total_assets","value":"2,406,086,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,406,086,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_6195F192CBDE, https://asof.is/claim/clm_6195F192CBDE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_6195F192CBDE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_34CC74560F05","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_81C9DAEE5D23","predicate":"total_equity","value":"1,155,905,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,155,905,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_81C9DAEE5D23, https://asof.is/claim/clm_81C9DAEE5D23, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_81C9DAEE5D23","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_16DE270CBEB7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_B60FF5975D9F","predicate":"cash_and_equivalents","value":"718,563,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 718,563,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_B60FF5975D9F, https://asof.is/claim/clm_B60FF5975D9F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_B60FF5975D9F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C9477D430932","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_E49939D6DEDB","predicate":"quarterly_revenue","value":"178,987,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 178,987,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_E49939D6DEDB, https://asof.is/claim/clm_E49939D6DEDB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_E49939D6DEDB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_72E202E696DB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_F0EB4C4B4423","predicate":"quarterly_net_income","value":"-170,060,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -170,060,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_F0EB4C4B4423, https://asof.is/claim/clm_F0EB4C4B4423, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm.","url":"https://asof.is/claim/clm_F0EB4C4B4423","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64459540A52F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"id":"clm_8D7D5AA15F63","predicate":"shares_outstanding","value":"238,081,533 shares","valid_from":"2014-07-25","valid_to":"2014-10-31","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 238,081,533 shares\", as of 2014-07-25 (until 2014-10-31). Claim clm_8D7D5AA15F63, https://asof.is/claim/clm_8D7D5AA15F63, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_8D7D5AA15F63","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_479F66F00F16","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_34EE023B80C3","predicate":"quarterly_net_income","value":"-159,382,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -159,382,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_34EE023B80C3, https://asof.is/claim/clm_34EE023B80C3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_34EE023B80C3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F0EB4C4B4423","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_46E7801D804E","predicate":"total_equity","value":"1,172,269,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,172,269,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_46E7801D804E, https://asof.is/claim/clm_46E7801D804E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_46E7801D804E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_81C9DAEE5D23","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_52B14B1D462C","predicate":"quarterly_revenue","value":"138,421,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 138,421,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_52B14B1D462C, https://asof.is/claim/clm_52B14B1D462C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_52B14B1D462C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E49939D6DEDB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_A8C0C28AF1BF","predicate":"cash_and_equivalents","value":"420,558,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 420,558,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_A8C0C28AF1BF, https://asof.is/claim/clm_A8C0C28AF1BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_A8C0C28AF1BF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B60FF5975D9F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_D9114AAA14BA","predicate":"quarterly_research_and_development","value":"224,780,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 224,780,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_D9114AAA14BA, https://asof.is/claim/clm_D9114AAA14BA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_D9114AAA14BA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_411488F61069","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_F90C0CD0E0F7","predicate":"quarterly_operating_income","value":"-180,835,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -180,835,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_F90C0CD0E0F7, https://asof.is/claim/clm_F90C0CD0E0F7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_F90C0CD0E0F7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_230B3E2BC570","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_F96409BD070A","predicate":"total_assets","value":"2,117,820,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,117,820,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_F96409BD070A, https://asof.is/claim/clm_F96409BD070A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm.","url":"https://asof.is/claim/clm_F96409BD070A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6195F192CBDE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-07-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-07-31"}},{"id":"clm_D207B55FE5A6","predicate":"shares_outstanding","value":"236,194,337 shares","valid_from":"2014-04-25","valid_to":"2014-07-25","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 236,194,337 shares\", as of 2014-04-25 (until 2014-07-25). Claim clm_D207B55FE5A6, https://asof.is/claim/clm_D207B55FE5A6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_D207B55FE5A6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8D7D5AA15F63","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_1085DB3D0A82","predicate":"total_assets","value":"2,197,108,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,197,108,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_1085DB3D0A82, https://asof.is/claim/clm_1085DB3D0A82, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_1085DB3D0A82","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F96409BD070A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_4AA01F0AE5BB","predicate":"quarterly_operating_income","value":"-216,388,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -216,388,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_4AA01F0AE5BB, https://asof.is/claim/clm_4AA01F0AE5BB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_4AA01F0AE5BB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F90C0CD0E0F7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_4CF2DBBF2865","predicate":"cash_and_equivalents","value":"424,045,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 424,045,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_4CF2DBBF2865, https://asof.is/claim/clm_4CF2DBBF2865, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_4CF2DBBF2865","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A8C0C28AF1BF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_4F43AE81E1E8","predicate":"quarterly_research_and_development","value":"238,963,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 238,963,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_4F43AE81E1E8, https://asof.is/claim/clm_4F43AE81E1E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_4F43AE81E1E8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D9114AAA14BA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_70C273FE1AD2","predicate":"quarterly_revenue","value":"118,451,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 118,451,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_70C273FE1AD2, https://asof.is/claim/clm_70C273FE1AD2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_70C273FE1AD2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_52B14B1D462C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_9AE7AF8EC0D1","predicate":"total_equity","value":"1,230,878,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,230,878,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_9AE7AF8EC0D1, https://asof.is/claim/clm_9AE7AF8EC0D1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_9AE7AF8EC0D1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46E7801D804E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_9DB52C5BBEAA","predicate":"quarterly_net_income","value":"-232,457,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -232,457,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_9DB52C5BBEAA, https://asof.is/claim/clm_9DB52C5BBEAA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm.","url":"https://asof.is/claim/clm_9DB52C5BBEAA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_34EE023B80C3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-05"}},{"id":"clm_E2A186C9E37B","predicate":"shares_outstanding","value":"235,771,942 shares","valid_from":"2014-02-05","valid_to":"2014-04-25","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 235,771,942 shares\", as of 2014-02-05 (until 2014-04-25). Claim clm_E2A186C9E37B, https://asof.is/claim/clm_E2A186C9E37B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_E2A186C9E37B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D207B55FE5A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_260A5D665F9C","predicate":"total_equity","value":"1,356,405,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,356,405,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_260A5D665F9C, https://asof.is/claim/clm_260A5D665F9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_260A5D665F9C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9AE7AF8EC0D1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_59D5E0CC1F00","predicate":"net_income","value":"-445,028,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -445,028,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_59D5E0CC1F00, https://asof.is/claim/clm_59D5E0CC1F00, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_59D5E0CC1F00","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E0C813E29FDB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_727E384A5333","predicate":"research_and_development","value":"918,783,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 918,783,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_727E384A5333, https://asof.is/claim/clm_727E384A5333, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_727E384A5333","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2F6A721A75E3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_8F39AD572FD3","predicate":"total_assets","value":"2,319,041,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,319,041,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_8F39AD572FD3, https://asof.is/claim/clm_8F39AD572FD3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_8F39AD572FD3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1085DB3D0A82","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_9BA598811A16","predicate":"cash_and_equivalents","value":"569,299,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 569,299,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_9BA598811A16, https://asof.is/claim/clm_9BA598811A16, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_9BA598811A16","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4CF2DBBF2865","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_A3A048BBF066","predicate":"operating_income","value":"-903,448,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -903,448,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_A3A048BBF066, https://asof.is/claim/clm_A3A048BBF066, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_A3A048BBF066","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_729B31AEC767","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_B995587F5A51","predicate":"revenue","value":"1,211,975,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 1,211,975,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_B995587F5A51, https://asof.is/claim/clm_B995587F5A51, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm.","url":"https://asof.is/claim/clm_B995587F5A51","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76E972477DD6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532014000015/0000875320-14-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-11T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2013, filed 2014-02-11"}},{"id":"clm_EB4B38E18AF2","predicate":"shares_outstanding","value":"233,756,871 shares","valid_from":"2013-10-31","valid_to":"2014-02-05","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 233,756,871 shares\", as of 2013-10-31 (until 2014-02-05). Claim clm_EB4B38E18AF2, https://asof.is/claim/clm_EB4B38E18AF2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_EB4B38E18AF2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2A186C9E37B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_31AFB2309D37","predicate":"quarterly_operating_income","value":"-134,065,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -134,065,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_31AFB2309D37, https://asof.is/claim/clm_31AFB2309D37, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_31AFB2309D37","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4AA01F0AE5BB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_393B542CC9D8","predicate":"cash_and_equivalents","value":"583,181,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 583,181,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_393B542CC9D8, https://asof.is/claim/clm_393B542CC9D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_393B542CC9D8","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9BA598811A16","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_4674F8E819AD","predicate":"total_assets","value":"2,582,748,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,582,748,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_4674F8E819AD, https://asof.is/claim/clm_4674F8E819AD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_4674F8E819AD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8F39AD572FD3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_48045D19FF6B","predicate":"quarterly_revenue","value":"221,700,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 221,700,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_48045D19FF6B, https://asof.is/claim/clm_48045D19FF6B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_48045D19FF6B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_70C273FE1AD2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_4D0F0C1EE546","predicate":"quarterly_research_and_development","value":"228,624,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 228,624,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_4D0F0C1EE546, https://asof.is/claim/clm_4D0F0C1EE546, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_4D0F0C1EE546","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4F43AE81E1E8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_6D0B6A2430B2","predicate":"total_equity","value":"1,264,888,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,264,888,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_6D0B6A2430B2, https://asof.is/claim/clm_6D0B6A2430B2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_6D0B6A2430B2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_260A5D665F9C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_E100CA9B87CC","predicate":"quarterly_net_income","value":"-124,132,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -124,132,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_E100CA9B87CC, https://asof.is/claim/clm_E100CA9B87CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm.","url":"https://asof.is/claim/clm_E100CA9B87CC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9DB52C5BBEAA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-07"}},{"id":"clm_BEFDB3212DCF","predicate":"shares_outstanding","value":"232,812,301 shares","valid_from":"2013-07-26","valid_to":"2013-10-31","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 232,812,301 shares\", as of 2013-07-26 (until 2013-10-31). Claim clm_BEFDB3212DCF, https://asof.is/claim/clm_BEFDB3212DCF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_BEFDB3212DCF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EB4B38E18AF2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_13FE3C35A2BF","predicate":"total_assets","value":"2,584,329,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,584,329,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_13FE3C35A2BF, https://asof.is/claim/clm_13FE3C35A2BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_13FE3C35A2BF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4674F8E819AD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_2152B7E19DEE","predicate":"quarterly_net_income","value":"-57,165,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -57,165,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_2152B7E19DEE, https://asof.is/claim/clm_2152B7E19DEE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_2152B7E19DEE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E100CA9B87CC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_246A631757AE","predicate":"quarterly_research_and_development","value":"222,455,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 222,455,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_246A631757AE, https://asof.is/claim/clm_246A631757AE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_246A631757AE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4D0F0C1EE546","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_802A10BA2903","predicate":"quarterly_operating_income","value":"-56,933,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -56,933,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_802A10BA2903, https://asof.is/claim/clm_802A10BA2903, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_802A10BA2903","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_31AFB2309D37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_95893F39D81D","predicate":"cash_and_equivalents","value":"531,247,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 531,247,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_95893F39D81D, https://asof.is/claim/clm_95893F39D81D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_95893F39D81D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_393B542CC9D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_D261B9E53F59","predicate":"total_equity","value":"1,322,453,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,322,453,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_D261B9E53F59, https://asof.is/claim/clm_D261B9E53F59, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_D261B9E53F59","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D0B6A2430B2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_FF8C09587BDA","predicate":"quarterly_revenue","value":"310,750,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 310,750,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_FF8C09587BDA, https://asof.is/claim/clm_FF8C09587BDA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm.","url":"https://asof.is/claim/clm_FF8C09587BDA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_48045D19FF6B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2013, filed 2013-08-02"}},{"id":"clm_F2071C89A470","predicate":"shares_outstanding","value":"221,400,864 shares","valid_from":"2013-04-26","valid_to":"2013-07-26","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 221,400,864 shares\", as of 2013-04-26 (until 2013-07-26). Claim clm_F2071C89A470, https://asof.is/claim/clm_F2071C89A470, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_F2071C89A470","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BEFDB3212DCF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_066255CCD67E","predicate":"total_equity","value":"746,115,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 746,115,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_066255CCD67E, https://asof.is/claim/clm_066255CCD67E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_066255CCD67E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D261B9E53F59","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_140090973306","predicate":"quarterly_operating_income","value":"-438,288,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -438,288,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_140090973306, https://asof.is/claim/clm_140090973306, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_140090973306","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_802A10BA2903","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_2B5B93D6737A","predicate":"total_assets","value":"2,392,234,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,392,234,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_2B5B93D6737A, https://asof.is/claim/clm_2B5B93D6737A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_2B5B93D6737A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_13FE3C35A2BF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_34EFC0C950B9","predicate":"quarterly_net_income","value":"-308,016,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -308,016,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_34EFC0C950B9, https://asof.is/claim/clm_34EFC0C950B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_34EFC0C950B9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2152B7E19DEE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_4285D9F06BA1","predicate":"cash_and_equivalents","value":"379,099,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 379,099,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_4285D9F06BA1, https://asof.is/claim/clm_4285D9F06BA1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_4285D9F06BA1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_95893F39D81D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_74FB230D7BFA","predicate":"quarterly_research_and_development","value":"218,095,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 218,095,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_74FB230D7BFA, https://asof.is/claim/clm_74FB230D7BFA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_74FB230D7BFA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_246A631757AE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_7FF4DCB7FD4C","predicate":"quarterly_revenue","value":"328,368,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 328,368,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_7FF4DCB7FD4C, https://asof.is/claim/clm_7FF4DCB7FD4C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm.","url":"https://asof.is/claim/clm_7FF4DCB7FD4C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FF8C09587BDA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_C9B18373B83D","predicate":"shares_outstanding","value":"218,188,628 shares","valid_from":"2013-02-15","valid_to":"2013-04-26","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 218,188,628 shares\", as of 2013-02-15 (until 2013-04-26). Claim clm_C9B18373B83D, https://asof.is/claim/clm_C9B18373B83D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_C9B18373B83D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F2071C89A470","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_117D40256E77","predicate":"net_income","value":"-107,032,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -107,032,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_117D40256E77, https://asof.is/claim/clm_117D40256E77, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_117D40256E77","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_59D5E0CC1F00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_16575A0C10F3","predicate":"total_assets","value":"2,759,288,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,759,288,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_16575A0C10F3, https://asof.is/claim/clm_16575A0C10F3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_16575A0C10F3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2B5B93D6737A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_1A11D785AD34","predicate":"revenue","value":"1,527,042,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 1,527,042,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_1A11D785AD34, https://asof.is/claim/clm_1A11D785AD34, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_1A11D785AD34","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B995587F5A51","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_2A4FE21B733E","predicate":"total_equity","value":"999,180,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 999,180,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_2A4FE21B733E, https://asof.is/claim/clm_2A4FE21B733E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_2A4FE21B733E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_066255CCD67E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_4F9C4EE9CB90","predicate":"operating_income","value":"2,332,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 2,332,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_4F9C4EE9CB90, https://asof.is/claim/clm_4F9C4EE9CB90, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_4F9C4EE9CB90","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A3A048BBF066","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_CA9105114287","predicate":"research_and_development","value":"806,185,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 806,185,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_CA9105114287, https://asof.is/claim/clm_CA9105114287, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_CA9105114287","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_727E384A5333","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_FCBF93D0B813","predicate":"cash_and_equivalents","value":"489,407,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 489,407,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_FCBF93D0B813, https://asof.is/claim/clm_FCBF93D0B813, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm.","url":"https://asof.is/claim/clm_FCBF93D0B813","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4285D9F06BA1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532013000009/0000875320-13-000009-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-03-01"}},{"id":"clm_70D8F6354992","predicate":"shares_outstanding","value":"216,827,066 shares","valid_from":"2012-10-26","valid_to":"2013-02-15","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 216,827,066 shares\", as of 2012-10-26 (until 2013-02-15). Claim clm_70D8F6354992, https://asof.is/claim/clm_70D8F6354992, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_70D8F6354992","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C9B18373B83D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_440DD76F9BF9","predicate":"quarterly_research_and_development","value":"200,161,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 200,161,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_440DD76F9BF9, https://asof.is/claim/clm_440DD76F9BF9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_440DD76F9BF9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_74FB230D7BFA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_68D80A12D2B9","predicate":"total_assets","value":"2,718,823,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,718,823,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_68D80A12D2B9, https://asof.is/claim/clm_68D80A12D2B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_68D80A12D2B9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_16575A0C10F3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_8B3F25617388","predicate":"quarterly_revenue","value":"336,006,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 336,006,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_8B3F25617388, https://asof.is/claim/clm_8B3F25617388, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_8B3F25617388","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7FF4DCB7FD4C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_C200AAD1B7D9","predicate":"quarterly_operating_income","value":"-1,071,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -1,071,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_C200AAD1B7D9, https://asof.is/claim/clm_C200AAD1B7D9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_C200AAD1B7D9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_140090973306","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_DD677E25C8F6","predicate":"total_equity","value":"1,027,733,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,027,733,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_DD677E25C8F6, https://asof.is/claim/clm_DD677E25C8F6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_DD677E25C8F6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A4FE21B733E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_E50A47FF19A4","predicate":"cash_and_equivalents","value":"436,886,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 436,886,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_E50A47FF19A4, https://asof.is/claim/clm_E50A47FF19A4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_E50A47FF19A4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FCBF93D0B813","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_F8030CD50108","predicate":"quarterly_net_income","value":"-57,543,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -57,543,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_F8030CD50108, https://asof.is/claim/clm_F8030CD50108, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm.","url":"https://asof.is/claim/clm_F8030CD50108","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_34EFC0C950B9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_F20A5D8DC03B","predicate":"shares_outstanding","value":"215,807,482 shares","valid_from":"2012-07-27","valid_to":"2012-10-26","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 215,807,482 shares\", as of 2012-07-27 (until 2012-10-26). Claim clm_F20A5D8DC03B, https://asof.is/claim/clm_F20A5D8DC03B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_F20A5D8DC03B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_70D8F6354992","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_0A5AAF6DC9F9","predicate":"quarterly_operating_income","value":"-10,770,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -10,770,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_0A5AAF6DC9F9, https://asof.is/claim/clm_0A5AAF6DC9F9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_0A5AAF6DC9F9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C200AAD1B7D9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_72E671723425","predicate":"total_equity","value":"1,037,773,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,037,773,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_72E671723425, https://asof.is/claim/clm_72E671723425, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_72E671723425","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DD677E25C8F6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_76A2F176E63C","predicate":"quarterly_net_income","value":"-64,931,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -64,931,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_76A2F176E63C, https://asof.is/claim/clm_76A2F176E63C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_76A2F176E63C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F8030CD50108","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_87BBE0E23F91","predicate":"quarterly_research_and_development","value":"196,544,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 196,544,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_87BBE0E23F91, https://asof.is/claim/clm_87BBE0E23F91, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_87BBE0E23F91","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_440DD76F9BF9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_D1DAC76653E3","predicate":"total_assets","value":"2,604,856,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,604,856,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_D1DAC76653E3, https://asof.is/claim/clm_D1DAC76653E3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_D1DAC76653E3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_68D80A12D2B9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_EDB18FEAB098","predicate":"quarterly_revenue","value":"418,305,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 418,305,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_EDB18FEAB098, https://asof.is/claim/clm_EDB18FEAB098, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_EDB18FEAB098","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8B3F25617388","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_FC85126D5926","predicate":"cash_and_equivalents","value":"454,061,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 454,061,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_FC85126D5926, https://asof.is/claim/clm_FC85126D5926, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm.","url":"https://asof.is/claim/clm_FC85126D5926","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E50A47FF19A4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-08-08"}},{"id":"clm_78F55C9D6D48","predicate":"shares_outstanding","value":"211,061,148 shares","valid_from":"2012-04-27","valid_to":"2012-07-27","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 211,061,148 shares\", as of 2012-04-27 (until 2012-07-27). Claim clm_78F55C9D6D48, https://asof.is/claim/clm_78F55C9D6D48, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_78F55C9D6D48","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F20A5D8DC03B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_7DA2AEFA0080","predicate":"total_equity","value":"930,498,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 930,498,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_7DA2AEFA0080, https://asof.is/claim/clm_7DA2AEFA0080, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_7DA2AEFA0080","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_72E671723425","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_85DA72CF3BE5","predicate":"quarterly_operating_income","value":"91,649,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 91,649,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_85DA72CF3BE5, https://asof.is/claim/clm_85DA72CF3BE5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_85DA72CF3BE5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0A5AAF6DC9F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_A3EAB937180F","predicate":"total_assets","value":"2,345,843,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,345,843,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_A3EAB937180F, https://asof.is/claim/clm_A3EAB937180F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_A3EAB937180F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D1DAC76653E3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_B1D95D9229AF","predicate":"cash_and_equivalents","value":"267,923,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 267,923,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_B1D95D9229AF, https://asof.is/claim/clm_B1D95D9229AF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_B1D95D9229AF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FC85126D5926","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_C0D5B06E732F","predicate":"quarterly_net_income","value":"91,590,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 91,590,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_C0D5B06E732F, https://asof.is/claim/clm_C0D5B06E732F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_C0D5B06E732F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76A2F176E63C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_CEDFEA389A43","predicate":"quarterly_research_and_development","value":"196,371,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 196,371,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_CEDFEA389A43, https://asof.is/claim/clm_CEDFEA389A43, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_CEDFEA389A43","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_87BBE0E23F91","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_D0A8C98B8F52","predicate":"quarterly_revenue","value":"438,737,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 438,737,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_D0A8C98B8F52, https://asof.is/claim/clm_D0A8C98B8F52, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_D0A8C98B8F52","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EDB18FEAB098","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_E8ED2497AD7B","predicate":"shares_outstanding","value":"210,335,993 shares","valid_from":"2012-02-08","valid_to":"2012-04-27","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 210,335,993 shares\", as of 2012-02-08 (until 2012-04-27). Claim clm_E8ED2497AD7B, https://asof.is/claim/clm_E8ED2497AD7B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_E8ED2497AD7B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78F55C9D6D48","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_15FE4534F8E1","predicate":"total_assets","value":"2,204,280,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,204,280,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_15FE4534F8E1, https://asof.is/claim/clm_15FE4534F8E1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_15FE4534F8E1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A3EAB937180F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_46A87149904E","predicate":"total_equity","value":"786,843,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 786,843,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_46A87149904E, https://asof.is/claim/clm_46A87149904E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_46A87149904E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7DA2AEFA0080","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_7FB96A1EC04F","predicate":"research_and_development","value":"707,706,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 707,706,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_7FB96A1EC04F, https://asof.is/claim/clm_7FB96A1EC04F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_7FB96A1EC04F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CA9105114287","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_84EBB48920A6","predicate":"cash_and_equivalents","value":"475,320,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 475,320,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_84EBB48920A6, https://asof.is/claim/clm_84EBB48920A6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_84EBB48920A6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B1D95D9229AF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_D6D7CB158831","predicate":"net_income","value":"29,574,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 29,574,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_D6D7CB158831, https://asof.is/claim/clm_D6D7CB158831, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_D6D7CB158831","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_117D40256E77","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_E814D4173C5E","predicate":"operating_income","value":"113,820,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 113,820,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_E814D4173C5E, https://asof.is/claim/clm_E814D4173C5E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_E814D4173C5E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4F9C4EE9CB90","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_EDAEC8A3D536","predicate":"revenue","value":"1,410,626,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 1,410,626,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_EDAEC8A3D536, https://asof.is/claim/clm_EDAEC8A3D536, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_EDAEC8A3D536","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1A11D785AD34","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_AA7202AF1645","predicate":"shares_outstanding","value":"208,566,194 shares","valid_from":"2011-10-28","valid_to":"2012-02-08","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 208,566,194 shares\", as of 2011-10-28 (until 2012-02-08). Claim clm_AA7202AF1645, https://asof.is/claim/clm_AA7202AF1645, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_AA7202AF1645","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E8ED2497AD7B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_0364D2508EA1","predicate":"total_assets","value":"2,091,998,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 2,091,998,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_0364D2508EA1, https://asof.is/claim/clm_0364D2508EA1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_0364D2508EA1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_15FE4534F8E1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_2E31B54439BF","predicate":"quarterly_net_income","value":"221,110,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 221,110,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_2E31B54439BF, https://asof.is/claim/clm_2E31B54439BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_2E31B54439BF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C0D5B06E732F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_51A871DDB6C2","predicate":"cash_and_equivalents","value":"542,545,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 542,545,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_51A871DDB6C2, https://asof.is/claim/clm_51A871DDB6C2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_51A871DDB6C2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_84EBB48920A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_56187F563316","predicate":"total_equity","value":"579,762,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 579,762,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_56187F563316, https://asof.is/claim/clm_56187F563316, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_56187F563316","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46A87149904E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_AFFDEC5591E2","predicate":"quarterly_revenue","value":"659,200,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 659,200,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_AFFDEC5591E2, https://asof.is/claim/clm_AFFDEC5591E2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_AFFDEC5591E2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D0A8C98B8F52","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_B00D340EC942","predicate":"quarterly_research_and_development","value":"189,052,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 189,052,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_B00D340EC942, https://asof.is/claim/clm_B00D340EC942, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_B00D340EC942","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CEDFEA389A43","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_B3AC75D212CF","predicate":"quarterly_operating_income","value":"215,707,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 215,707,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_B3AC75D212CF, https://asof.is/claim/clm_B3AC75D212CF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_B3AC75D212CF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_85DA72CF3BE5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_47B306C70D65","predicate":"shares_outstanding","value":"208,087,899 shares","valid_from":"2011-07-29","valid_to":"2011-10-28","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 208,087,899 shares\", as of 2011-07-29 (until 2011-10-28). Claim clm_47B306C70D65, https://asof.is/claim/clm_47B306C70D65, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_47B306C70D65","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AA7202AF1645","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_0816B23FB77A","predicate":"cash_and_equivalents","value":"458,195,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 458,195,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_0816B23FB77A, https://asof.is/claim/clm_0816B23FB77A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_0816B23FB77A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_51A871DDB6C2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_0CB375426AF0","predicate":"quarterly_revenue","value":"114,424,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 114,424,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_0CB375426AF0, https://asof.is/claim/clm_0CB375426AF0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_0CB375426AF0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AFFDEC5591E2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_1F567078AF69","predicate":"total_equity","value":"307,549,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 307,549,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_1F567078AF69, https://asof.is/claim/clm_1F567078AF69, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_1F567078AF69","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56187F563316","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_46C52FB158CE","predicate":"quarterly_net_income","value":"-174,069,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -174,069,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_46C52FB158CE, https://asof.is/claim/clm_46C52FB158CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_46C52FB158CE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2E31B54439BF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_6B7C068E138D","predicate":"total_assets","value":"1,763,100,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,763,100,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_6B7C068E138D, https://asof.is/claim/clm_6B7C068E138D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_6B7C068E138D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0364D2508EA1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_B5FD1F0507D0","predicate":"quarterly_research_and_development","value":"173,604,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 173,604,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_B5FD1F0507D0, https://asof.is/claim/clm_B5FD1F0507D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_B5FD1F0507D0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B00D340EC942","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_D1B891CE165A","predicate":"quarterly_operating_income","value":"-165,890,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -165,890,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_D1B891CE165A, https://asof.is/claim/clm_D1B891CE165A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_D1B891CE165A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B3AC75D212CF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_AFEA9E22E536","predicate":"shares_outstanding","value":"205,997,844 shares","valid_from":"2011-04-28","valid_to":"2011-07-29","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 205,997,844 shares\", as of 2011-04-28 (until 2011-07-29). Claim clm_AFEA9E22E536, https://asof.is/claim/clm_AFEA9E22E536, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_AFEA9E22E536","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_47B306C70D65","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_06E54341B7F1","predicate":"quarterly_revenue","value":"73,662,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 73,662,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_06E54341B7F1, https://asof.is/claim/clm_06E54341B7F1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_06E54341B7F1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0CB375426AF0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_35956A6601A7","predicate":"quarterly_research_and_development","value":"158,612,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 158,612,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_35956A6601A7, https://asof.is/claim/clm_35956A6601A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_35956A6601A7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B5FD1F0507D0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_6FF0398AE57E","predicate":"total_equity","value":"391,672,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 391,672,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_6FF0398AE57E, https://asof.is/claim/clm_6FF0398AE57E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_6FF0398AE57E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1F567078AF69","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_DBCB7DA025BF","predicate":"total_assets","value":"1,538,487,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,538,487,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_DBCB7DA025BF, https://asof.is/claim/clm_DBCB7DA025BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_DBCB7DA025BF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6B7C068E138D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_ECF62E043F01","predicate":"quarterly_net_income","value":"-176,096,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -176,096,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_ECF62E043F01, https://asof.is/claim/clm_ECF62E043F01, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm.","url":"https://asof.is/claim/clm_ECF62E043F01","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46C52FB158CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-10"}},{"id":"clm_EF4EBE9A383C","predicate":"quarterly_operating_income","value":"-159,899,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -159,899,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_EF4EBE9A383C, https://asof.is/claim/clm_EF4EBE9A383C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_EF4EBE9A383C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D1B891CE165A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_F97987974B05","predicate":"cash_and_equivalents","value":"446,536,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 446,536,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_F97987974B05, https://asof.is/claim/clm_F97987974B05, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm.","url":"https://asof.is/claim/clm_F97987974B05","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0816B23FB77A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-06"}},{"id":"clm_995698503836","predicate":"shares_outstanding","value":"204,412,712 shares","valid_from":"2011-02-09","valid_to":"2011-04-28","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 204,412,712 shares\", as of 2011-02-09 (until 2011-04-28). Claim clm_995698503836, https://asof.is/claim/clm_995698503836, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_995698503836","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AFEA9E22E536","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_6694DF685051","predicate":"net_income","value":"-754,626,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -754,626,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_6694DF685051, https://asof.is/claim/clm_6694DF685051, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_6694DF685051","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D6D7CB158831","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_6F397338265E","predicate":"cash_and_equivalents","value":"243,197,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 243,197,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_6F397338265E, https://asof.is/claim/clm_6F397338265E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_6F397338265E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F97987974B05","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_7AB4898F104F","predicate":"research_and_development","value":"637,416,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 637,416,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_7AB4898F104F, https://asof.is/claim/clm_7AB4898F104F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_7AB4898F104F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7FB96A1EC04F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_9472043EC2FF","predicate":"operating_income","value":"-696,077,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -696,077,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_9472043EC2FF, https://asof.is/claim/clm_9472043EC2FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_9472043EC2FF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E814D4173C5E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_A50C566EACEB","predicate":"revenue","value":"143,370,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 143,370,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_A50C566EACEB, https://asof.is/claim/clm_A50C566EACEB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_A50C566EACEB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EDAEC8A3D536","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_ABDC2E967578","predicate":"total_equity","value":"503,973,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 503,973,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_ABDC2E967578, https://asof.is/claim/clm_ABDC2E967578, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_ABDC2E967578","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6FF0398AE57E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_CE17430C757C","predicate":"total_assets","value":"1,725,446,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,725,446,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_CE17430C757C, https://asof.is/claim/clm_CE17430C757C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_CE17430C757C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DBCB7DA025BF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_69DF2085CFCB","predicate":"shares_outstanding","value":"203,194,222 shares","valid_from":"2010-10-21","valid_to":"2011-02-09","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 203,194,222 shares\", as of 2010-10-21 (until 2011-02-09). Claim clm_69DF2085CFCB, https://asof.is/claim/clm_69DF2085CFCB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_69DF2085CFCB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_995698503836","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_185D3E640F90","predicate":"quarterly_net_income","value":"-208,957,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2011-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -208,957,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_185D3E640F90, https://asof.is/claim/clm_185D3E640F90, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm.","url":"https://asof.is/claim/clm_185D3E640F90","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ECF62E043F01","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-03"}},{"id":"clm_6AC662175277","predicate":"total_equity","value":"650,096,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 650,096,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_6AC662175277, https://asof.is/claim/clm_6AC662175277, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_6AC662175277","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ABDC2E967578","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_8982B813454B","predicate":"quarterly_operating_income","value":"-199,588,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -199,588,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_8982B813454B, https://asof.is/claim/clm_8982B813454B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_8982B813454B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF4EBE9A383C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_99FB6CAA75AD","predicate":"cash_and_equivalents","value":"569,901,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 569,901,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_99FB6CAA75AD, https://asof.is/claim/clm_99FB6CAA75AD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_99FB6CAA75AD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6F397338265E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_A2ABBC5D4946","predicate":"quarterly_revenue","value":"23,795,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 23,795,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_A2ABBC5D4946, https://asof.is/claim/clm_A2ABBC5D4946, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_A2ABBC5D4946","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_06E54341B7F1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_C3D8BF48EB7E","predicate":"total_assets","value":"1,888,829,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,888,829,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_C3D8BF48EB7E, https://asof.is/claim/clm_C3D8BF48EB7E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_C3D8BF48EB7E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CE17430C757C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_D6506FFCBC0C","predicate":"quarterly_research_and_development","value":"170,434,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 170,434,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_D6506FFCBC0C, https://asof.is/claim/clm_D6506FFCBC0C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_D6506FFCBC0C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_35956A6601A7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_115794095037","predicate":"shares_outstanding","value":"202,831,612 shares","valid_from":"2010-07-29","valid_to":"2010-10-21","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 202,831,612 shares\", as of 2010-07-29 (until 2010-10-21). Claim clm_115794095037, https://asof.is/claim/clm_115794095037, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_115794095037","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_69DF2085CFCB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_0E4918D23EC7","predicate":"total_equity","value":"827,135,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 827,135,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_0E4918D23EC7, https://asof.is/claim/clm_0E4918D23EC7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_0E4918D23EC7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6AC662175277","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_5B82DB4B1ACF","predicate":"total_assets","value":"1,654,202,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,654,202,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_5B82DB4B1ACF, https://asof.is/claim/clm_5B82DB4B1ACF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_5B82DB4B1ACF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C3D8BF48EB7E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_66CCBB904B9A","predicate":"quarterly_operating_income","value":"-169,573,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -169,573,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_66CCBB904B9A, https://asof.is/claim/clm_66CCBB904B9A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_66CCBB904B9A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8982B813454B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_8F60B25A1E7E","predicate":"quarterly_net_income","value":"-200,006,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2011-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: -200,006,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_8F60B25A1E7E, https://asof.is/claim/clm_8F60B25A1E7E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm.","url":"https://asof.is/claim/clm_8F60B25A1E7E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_185D3E640F90","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-09"}},{"id":"clm_91E848597DF5","predicate":"quarterly_revenue","value":"31,622,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 31,622,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_91E848597DF5, https://asof.is/claim/clm_91E848597DF5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_91E848597DF5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A2ABBC5D4946","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_A76FEE254CA5","predicate":"quarterly_research_and_development","value":"155,082,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 155,082,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_A76FEE254CA5, https://asof.is/claim/clm_A76FEE254CA5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_A76FEE254CA5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D6506FFCBC0C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_FFDB6607C3CE","predicate":"cash_and_equivalents","value":"337,608,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 337,608,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_FFDB6607C3CE, https://asof.is/claim/clm_FFDB6607C3CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_FFDB6607C3CE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_99FB6CAA75AD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_5547C6BF3A52","predicate":"shares_outstanding","value":"202,202,912 shares","valid_from":"2010-04-22","valid_to":"2010-07-29","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 202,202,912 shares\", as of 2010-04-22 (until 2010-07-29). Claim clm_5547C6BF3A52, https://asof.is/claim/clm_5547C6BF3A52, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_5547C6BF3A52","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_115794095037","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_19213C00D007","predicate":"total_equity","value":"990,612,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 990,612,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_19213C00D007, https://asof.is/claim/clm_19213C00D007, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_19213C00D007","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E4918D23EC7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_6F9D9EB7890A","predicate":"quarterly_operating_income","value":"-160,282,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -160,282,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_6F9D9EB7890A, https://asof.is/claim/clm_6F9D9EB7890A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_6F9D9EB7890A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_66CCBB904B9A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_704DCF1A9448","predicate":"cash_and_equivalents","value":"396,547,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 396,547,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_704DCF1A9448, https://asof.is/claim/clm_704DCF1A9448, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_704DCF1A9448","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FFDB6607C3CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_71D593846901","predicate":"total_assets","value":"1,770,302,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,770,302,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_71D593846901, https://asof.is/claim/clm_71D593846901, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_71D593846901","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B82DB4B1ACF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_803A751AACB0","predicate":"quarterly_revenue","value":"22,429,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 22,429,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_803A751AACB0, https://asof.is/claim/clm_803A751AACB0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_803A751AACB0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_91E848597DF5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_D2BF7F6D2E9B","predicate":"quarterly_research_and_development","value":"143,012,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 143,012,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_D2BF7F6D2E9B, https://asof.is/claim/clm_D2BF7F6D2E9B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_D2BF7F6D2E9B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A76FEE254CA5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_0B1A1540D1B7","predicate":"cash_and_equivalents","value":"446,658,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 446,658,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_0B1A1540D1B7, https://asof.is/claim/clm_0B1A1540D1B7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_0B1A1540D1B7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_704DCF1A9448","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_25D63D0ED4EF","predicate":"net_income","value":"-642,178,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2012-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -642,178,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_25D63D0ED4EF, https://asof.is/claim/clm_25D63D0ED4EF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm.","url":"https://asof.is/claim/clm_25D63D0ED4EF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6694DF685051","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746912001298/0001047469-12-001298-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-22"}},{"id":"clm_4369373195D9","predicate":"total_assets","value":"1,955,488,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 1,955,488,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_4369373195D9, https://asof.is/claim/clm_4369373195D9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_4369373195D9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71D593846901","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_7210AEE2240D","predicate":"research_and_development","value":"550,274,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 550,274,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_7210AEE2240D, https://asof.is/claim/clm_7210AEE2240D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_7210AEE2240D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7AB4898F104F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_72998EF97E5B","predicate":"revenue","value":"101,889,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 101,889,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_72998EF97E5B, https://asof.is/claim/clm_72998EF97E5B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_72998EF97E5B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A50C566EACEB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_9AF280BB8EE3","predicate":"operating_income","value":"-614,012,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -614,012,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_9AF280BB8EE3, https://asof.is/claim/clm_9AF280BB8EE3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_9AF280BB8EE3","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9472043EC2FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_9E65725B61EB","predicate":"total_equity","value":"1,096,346,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 1,096,346,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_9E65725B61EB, https://asof.is/claim/clm_9E65725B61EB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_9E65725B61EB","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_19213C00D007","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_CD892C0A824B","predicate":"quarterly_operating_income","value":"-148,233,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -148,233,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_CD892C0A824B, https://asof.is/claim/clm_CD892C0A824B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_CD892C0A824B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6F9D9EB7890A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_E5A0F7F2EB85","predicate":"quarterly_research_and_development","value":"132,132,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 132,132,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_E5A0F7F2EB85, https://asof.is/claim/clm_E5A0F7F2EB85, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_E5A0F7F2EB85","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D2BF7F6D2E9B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_F77D600A24ED","predicate":"cash_and_equivalents","value":"559,133,000 United States dollar","valid_from":"2009-09-30","valid_to":"2009-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 559,133,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_F77D600A24ED, https://asof.is/claim/clm_F77D600A24ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_F77D600A24ED","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0B1A1540D1B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_FCBA634A768D","predicate":"quarterly_revenue","value":"24,957,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 24,957,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_FCBA634A768D, https://asof.is/claim/clm_FCBA634A768D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm.","url":"https://asof.is/claim/clm_FCBA634A768D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_803A751AACB0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-10-28"}},{"id":"clm_21238AD57FDF","predicate":"quarterly_operating_income","value":"-157,167,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -157,167,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_21238AD57FDF, https://asof.is/claim/clm_21238AD57FDF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_21238AD57FDF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CD892C0A824B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_2E63C80C1EC9","predicate":"cash_and_equivalents","value":"408,949,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 408,949,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_2E63C80C1EC9, https://asof.is/claim/clm_2E63C80C1EC9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_2E63C80C1EC9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F77D600A24ED","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_807DBFE23E9F","predicate":"quarterly_research_and_development","value":"139,331,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 139,331,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_807DBFE23E9F, https://asof.is/claim/clm_807DBFE23E9F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_807DBFE23E9F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E5A0F7F2EB85","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_8CAD8C9EBAFE","predicate":"quarterly_revenue","value":"19,064,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2010-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 19,064,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_8CAD8C9EBAFE, https://asof.is/claim/clm_8CAD8C9EBAFE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm.","url":"https://asof.is/claim/clm_8CAD8C9EBAFE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FCBA634A768D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-08-03"}},{"id":"clm_8EDF57286E75","predicate":"quarterly_revenue","value":"23,979,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 23,979,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_8EDF57286E75, https://asof.is/claim/clm_8EDF57286E75, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_8EDF57286E75","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8CAD8C9EBAFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_ADBE4057ECC4","predicate":"quarterly_operating_income","value":"-161,893,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: -161,893,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_ADBE4057ECC4, https://asof.is/claim/clm_ADBE4057ECC4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_ADBE4057ECC4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_21238AD57FDF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_BEF2FDEB0A7D","predicate":"quarterly_research_and_development","value":"143,581,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 143,581,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_BEF2FDEB0A7D, https://asof.is/claim/clm_BEF2FDEB0A7D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_BEF2FDEB0A7D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_807DBFE23E9F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_DAD4C578295B","predicate":"cash_and_equivalents","value":"602,199,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 602,199,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_DAD4C578295B, https://asof.is/claim/clm_DAD4C578295B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm.","url":"https://asof.is/claim/clm_DAD4C578295B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2E63C80C1EC9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-03"}},{"id":"clm_393679081B64","predicate":"total_equity","value":"238,874,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 238,874,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_393679081B64, https://asof.is/claim/clm_393679081B64, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_393679081B64","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9E65725B61EB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_3F47912035B4","predicate":"revenue","value":"175,504,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 175,504,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_3F47912035B4, https://asof.is/claim/clm_3F47912035B4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_3F47912035B4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_72998EF97E5B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_9DFE9C7313E6","predicate":"research_and_development","value":"516,912,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 516,912,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_9DFE9C7313E6, https://asof.is/claim/clm_9DFE9C7313E6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_9DFE9C7313E6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7210AEE2240D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_FAD35E124DA4","predicate":"cash_and_equivalents","value":"389,115,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 389,115,000 United States dollar\", as of 2008-12-31 (until 2009-03-31). Claim clm_FAD35E124DA4, https://asof.is/claim/clm_FAD35E124DA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_FAD35E124DA4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DAD4C578295B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_FEC47F071AB0","predicate":"operating_income","value":"-462,708,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -462,708,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_FEC47F071AB0, https://asof.is/claim/clm_FEC47F071AB0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_FEC47F071AB0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9AF280BB8EE3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_95E62B146772","predicate":"cash_and_equivalents","value":"355,663,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 355,663,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_95E62B146772, https://asof.is/claim/clm_95E62B146772, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_95E62B146772","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FAD35E124DA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_ACFA9A6B78BD","predicate":"total_equity","value":"271,295,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 271,295,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_ACFA9A6B78BD, https://asof.is/claim/clm_ACFA9A6B78BD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm.","url":"https://asof.is/claim/clm_ACFA9A6B78BD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_393679081B64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000104746911001025/0001047469-11-001025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-17T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2010, filed 2011-02-17"}},{"id":"clm_2D9EFA2C2469","predicate":"state_of_incorporation","value":"MA","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals state of incorporation: MA\", undated. Claim clm_2D9EFA2C2469, https://asof.is/claim/clm_2D9EFA2C2469, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_2D9EFA2C2469","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_572849379A15","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_572849379A15, https://asof.is/claim/clm_572849379A15, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_572849379A15","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_725C8AE3FDC6","predicate":"ticker","value":"VRTX","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals ticker: VRTX\", undated. Claim clm_725C8AE3FDC6, https://asof.is/claim/clm_725C8AE3FDC6, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_725C8AE3FDC6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7E8737D65987","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals fiscal year end: 12-31\", undated. Claim clm_7E8737D65987, https://asof.is/claim/clm_7E8737D65987, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_7E8737D65987","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A5822A229828","predicate":"headquarters","value":"Boston","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals headquarters: Boston\", undated. Claim clm_A5822A229828, https://asof.is/claim/clm_A5822A229828, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_A5822A229828","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B527C44C89E1","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals listed on: Nasdaq\", undated. Claim clm_B527C44C89E1, https://asof.is/claim/clm_B527C44C89E1, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_B527C44C89E1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E5A558D9CC9E","predicate":"registrant_name","value":"VERTEX PHARMACEUTICALS INC / MA","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals registrant name: VERTEX PHARMACEUTICALS INC / MA\", undated. Claim clm_E5A558D9CC9E, https://asof.is/claim/clm_E5A558D9CC9E, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_E5A558D9CC9E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E8D76EDFB1A2","predicate":"cik","value":"0000875320","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cik: 0000875320\", undated. Claim clm_E8D76EDFB1A2, https://asof.is/claim/clm_E8D76EDFB1A2, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_E8D76EDFB1A2","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}